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Abstract
Alzheimer’s  Disease (AD) is  the most  common form of  dementia,  recognized by the
World Health Organization as a global public health priority. It is a complex pathology
characterized by the accumulation of the Amyloid-β (Aβ) peptide as extracellular plaques
and of the intracellullar neuro fibrillary tangles (NFT) alongside with different events,
such as chronic neuroinflammation and astrogliosis. None of the existing biomarkers is
simultaneously specific for the pathology and sensitive to its progression. Metabolic and
functional alterations are the earliest events described in the AD pathological cascade but
shared with other form of dementia, while specific structural alterations occurs in a later
stage of the disease. The use of transgenic models could simplify the development of new
imaging biomarkers that would enable early diagnosis and making new treatments more
effective.  The objective of this work was to develop  a multi-modal panel of magnetic
resonance imaging (MRI) techniques and automated analysis pipelines, characterized by a
high translational impact, in order to investigate the metabolic, functional and structural
alterations  in  the  brains  of  AD  transgenic  models.  Results  obtained  in  the  APP23
transgenic mouse show that chemical exchange saturation transfer (CEST) imaging can
be used  to  detect  alterations  in  the  brain  uptake  of  the  glucose  analogue  2-deoxy-d-
glucose (2DG) with a better  resolution than PET and without the need of radioactive
tracers.  Moreover,  a longitudinal  study  highlighted  that  significant  structural  and
metabolic alterations can be found only in a late stage of the pathology. Furthermore, an
advanced pipeline for the analysis of the rodent brain functional connectivity has been
developed.  This  thesis  demonstrates  that  the  advantage  to  the  experimental  design
adopted is simplifying longitudinal studies of the same animal cohort. The translation of
the  analysis  pipelines  adopted  in  human  studies  enables  more  powerful  results  and
reduces the number of animals involved in research.  
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Chapter 1: Introduction
1.1 – Alzheimer’s Disease
Dementia  is  a  clinical  syndrome  caused  by  progressive  neurodegeneration,  it  is
characterized  by  the  deterioration  in  cognitive  abilities  and  capacity  of  independent
living.  Recent  estimates  described  that  in  2010  over  35  million  people  lived  with
dementia  world-wide.  As the population continues  to  age,  this  number is  expected to
double every 20 years reaching 115 million in 2050 (Prince et al., 2013). 
First described in 1906 by the German psychiatrist and neuropathologist Alois Alzheimer
and named after him, Alzheimer’s Disease (AD) is the most common form of dementia.
Recognized by the World Health Organization as a global public health priority, it affects
approximately 26 million people world-wide  (Lane et al.,  2018).  Although the disease
progression rate varies between patients, a person affected by AD lives four to eight years
after diagnosis but, depending on other factors, can live as long as 20 years (Alzheimer’s
Assotiations  2018).  AD symptoms worsen over time and can be described by a  slow
decline in memory, thinking and reasoning skills. Three categories have been defined to
describe AD stages: Firstly a long and asymptomatic phase called preclinical stage, when
pathological processes begins but there are not clincal signs of the disease. Subsequently,
a prodromal stage called mild cognitive impairment (MCI) when mild symptoms appear
with  minimal  impairment  in  instrumental  activities  of  daily  living.  Finally  the  AD
dementia phase when symptoms are severe and patients lose the ability to respond to their
environment,  to  carry  on  a  conversation  and,  eventually,  to  control  movement
(Alzheimer’s Assotiations 2018).
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Pathologically,   AD can  be  considered  as  a  complex  interplay  of  different  processes
characterized by three main type of lesions (Figure 1): those related to accumulation of
proteins, those that are due to the reactive processes such as inflammation and finally
those that are due to plasticity losses of neurons and synapses that result in macroscopic
brain atrophy in an advanced state of the disease (Duyckaerts et al., 2009). 
The underlying cause of the AD is not known in most of the cases. However, as shown in
Figure 2, a small proportion of early-onset AD cases are due to familiar genetic mutations
in  one  of  three  genes:  those  encoding  amyloid  precursor  protein  (APP),  presenilin  1
(PSEN1) and presenilin 2 (PSEN2) which are components of secretases that are involved
into the processing of amyloid-beta (Aβ) peptide.  The majority of AD cases are called
sporadic forms of AD which occur generally in people over 65 years of age,  without
obvious  familial  aggregation.  A  number  of  genes  have  been  identified  which  are
associated with a greatly increased risk of developing late onset. Among all of these, the
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Figure  1:  Neuropathology  in  the  hippocampus  of  healthy  controls  subject  and  AD  patients.  (A)
Diaminobenzidine (DAB) staining using the 6E10 antibody in hippocampal slices shows the presence of
dense-core amyloid-positive plaques (arrows), which are absent in controls. (B) Immunohistochemistry with
the AT8 antibody also shows AT8-positive senile plaques (arrows) and neurofibrillary tangles (asterisk), also
revealing fiber-like structures resembling distorted neurites. (C) GFAP immunostaining reveals the presence
of astrocytes with normal fine radial processes in the control brain; in the contrary, in the hippocampus of
AD patients, several clusters of astrocytes with thick radial processes are observed. (Scale bars = 20μm). (D)
In  an  advanced  state  of  the  disease,  macroscopic  brain  atrophy  and  enlargement  of  ventricles  can  be
identified as a result of the ongoing neural loss. Adapted from  (Alves et al., 2016)
apolipoprotein E (ApoE) is the one which is associated with the most elevated risk for
developing AD. It is a cholesterol carrier that supports lipid transport and injury repair in
the brain  (Mahley and Rall,  2000).  Individuals  carrying the ε4 allele  have more than
seven times increased risk of developing AD compared with those carrying the more
common ε3 allele, whereas the ε2 allele was associated with a decreased risk. However, it
remains unclear how Apoε4 is able to influences AD onset and progression (J. Kim et al.,
2009; C.-C. Liu et al., 2013).  
Figure 2: Risk-increasing effects (vertical axis) plotted against prevalence in general
population  (horizontal  axis)  between  either  causative  or  susceptible  genes/loci.
(Yamazaki et al., 2016)
A huge  number  of  studies  have  focused  on  AD  pathogeneses  proposing  different
hypothesis. Nonetheless, the precise etiologies and pathogeneses of AD still remain to be
clarified,  especially  the molecular  pathways at  the bottom of the various pathological
alterations that impair the cognitive functions related to learning and memory. 
The  “amyloid  hypothesis” is  the  most  widely  accepted.  It  posits  that  the  amyloid
plaques, formed by aggregates of amyloid-β are central to AD pathogenesis. Studying the
familiar mutations of APP, PSEN1 and PSEN2 genes it has been found that the altered
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production (Figure 3) and clearance of the Aβ peptide cause its deposition in the form of
plaques in the brain parenchyma (Hardy and Allsop, 1991). In particular, these familiar
genetic mutations results in a preferred amyloidogenic pathway producing the Aβ1-42 form,
with 42 amino acid length, which have higher self aggregation than the Aβ1-40 peptide
(Scheltens et al., 2016).
Figure  3:  For the peptide amyloid-β to be released into the space between cells, the
external portion of the membrane protein APP must be first cleaved off by the enzyme
β-secretase. The enzime γ-secretase then cuts the remaining membrane-bound portion
of the protein, freeing amyloid-β. Because γ-secretase can cut APP at a number of
sites, the length of  amyloid-β can vary. (Mucke, 2009)
Extracellular  Aβ  accumulation  may  also  involve  vessel  walls  of  arteries,  veins  and
capillaries (Figure 4). Small Aβ aggregates, called oligomers, have been described to be
more toxic than mature fibrils and associated with a cognitive decline (Ferreira and Klein,
2011). 
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Figure  4:  AD  pathological  cascade.  (1)  Processing  of  the  APP  at  cell
membrane  level.  (2)  In  the  space  between  neurons,  amiloyd-β  forms
oligomers that are thought to disrupt the function of synapses. (3) Fibrils of
amyloid- β oligomers aggregate into plaques, which interfere with function of
neurons.  (4)  Amyloid-β deposits  outside cells  and in  blood vessels  of  the
brain activate immune cells called microglial cells. This triggers the release of
inflammatory mediators and might contribute to synaptic loss. (5) Misfolded
tau aggregates into NFT inside neurons displacing intracellular organelles. (6)
Misfolded  tau  pass  through synapses  to  other  neurons,  where  it  catalyses
further misfolding tau.  Adapted from  (“The amyloid hypothesis on trial.  -
PubMed - NCBI,” n.d.).
Tau proteins are members of the microtubule-associated protein family, and are normally
expressed in neurons, where they have a fundamental role in maintaining the neuronal
microtubule network. Microtubules are involved in maintaining the cell shape and serve
as  tracks  for  axonal  transport.  Tau  proteins  also  establish  some  links  between
microtubules and other cytoskeletal elements or proteins (Buée et al., 2000).  In AD, the
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APP cleavage products  can activate  the  glycogen synthase  kinase  3β (GSKβ) protein
causing  and  abnormal  tau  hyperphosphorylation  that  lead  to  the  formation  of
neurofibrillary tangles (NFT)  (Grundke-Iqbal et al.,  1986; Hooper et  al.,  2008). These
NFT may accumulates in the cell body of the neuron but also in the dendrites as neuropil
threads  and  in  the  axons  forming  the  senile  plaque  neuritic  corona,  Figure  4.  Other
mutations such as DYRK1A (Janel et al., 2014) or Tau are involved in the NFT formation.
Figure 5: AD evolution a) The color scale represents the first point in the disease
relative  to  estimated  years  to  onset  at  which  rates  of  biomarker.  Increased  Aβ
deposition precedes hypometabolism that is followed by cortical thinning. (Gordon
et al., 2018). b) Spreading of tau pathology in Alzheimer Disease.  (Candela et al.,
2013)
The progression of Aβ deposition, Figure 5a, begins in the neocortex, and evolves to the
allocortex, to the subcortical structures and finally to the cerebellum. However, high inter-
individual variability of the Aβ deposition was observed in early stages, making difficult
the evaluation of the disease  (Mann et al.,  2001).  The impairment in cerebral glucose
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metabolism is  an  invariant  pathophysiological  feature  in  AD and its  occurrence  may
precedes  cognitive  dysfunction  for  decades  (Cunnane et  al.,  2011;  Jack  et  al.,  2010).
Increased Aβ deposition precedes hypometabolism that is followed by cortical thinning
(Gordon et al., 2018). In contrast to Aβ deposition, the spread of NFT in the bran has been
described with little variations between subjects, and its progression was classified into
six  different  stages  (Braak  and  Braak,  1991).  It  begins  from  the  entorhinal  cortex,
spreading to the hippocampus, and finally to the other parts of the isocortex (Figure 5b).
Both depositions increase with age, but stages 1 of the NFT deposition can develop before
the Aβ pathology (Braak and Del Tredici, 2014; Johnson et al., 2016). 
1.1.1 – Diagnosis of AD
There are no validated models able to recapitulate the full pathological spectrum of the
disease  and  the  definitive  diagnosis  is  still  based  on  histological  confirmation  at
postmortem examination. The AD diagnosis process is complicated by the presence of
early symptoms that are shared with other neurological disorders. 
An ideal  biomarker  would  allow the  clinician  to  distinguish  AD form other  form of
dementia,  such as  vascular  dementia,  fronto  temporal  dementia  (FTD) or  Lewy body
dementia (LBD).  As shown in  Figure 6, there is not a single imaging biomarker that is
specific for the pathology but also to the disease progression. The metabolic impairment
occurs in an early stage of the disease but it is shared with other forms of dementia, on the
other side, the amyloid deposition is specific for AD but reaches a plateau by the mild
cognitive impairment stage (MCI).  Since, none of the existing biomarkers can fulfill all
the conditions needed, a combination of the existing biomarkers is needed.
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Figure  6:  Theoretical  model  describing  the  natural  progression  of  cognitive  and  biological
markers of AD(Frisoni et al., 2010)
The diagnostic criteria have been recently updated, allowing the identification of the stage
pathology,  by  the  integration  of  the  clinical  evaluation  of  cognitive  dysfunction  by
neuropsychological tests  (Scheltens et al., 2016) with the so-called A/T/N classification
(Figure 7), where  “A” refers to the value of amyloid biomarkers; “T” to the value of a tau
biomarkers; and “N,” to biomarkers of neurodegeneration or neuronal injury (Jack et al.,
2018,  2016).  Even if  cognitive  impairment  evaluations  provides  valuable  information
about  the  societal  burden of  cognitive  disability,  amnestic  multidomain  dementia  and
other variants are not synonymous with the presence of Aβ deposition and neurofibrillary
degeneration. On the other hand, the absence of amnestic dementia is not synonymous
with  the  absence  of  these  hallmark  lesions  of  AD  and  preclinical  stage  cannot  be
ascertained  without  the  use  of  biomarkers.  Up  to  60%  of  cognitively  unimpaired
individuals  over  age  80  years  have  AD  neuropathologic  changes  at  autopsy  or  by
biomarkers  (Nelson et al., 2011, 2007; Serrano-Pozo et al., 2014). Thus, the use of just
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cognitive evaluation in the clinical diagnosis of “AD” to ascertain absence of disease is
associated with an error rate exceeding 50% (Jack et al., 2018).
Figure 7: Risk of short-term cognitive decline based on the biomarker profile and cognitive stage.
The sign beside the biomarker letter indicate whether it’s positive or negative. When the rate of
short term clinical progression is expected to be low the background color is white and gets darker
when the expected progression rate is higher  (Jack et al., 2018)
1.1.2 – Amyloid and Tau markers
Amyloid and tau deposition are the first events that occur in a preclinical stage of the
pathology. But, since this deposition already reaches a plateau by the MCI stage, they
cannot be considered good markers for the progression of the pathology in the clinical
stage of the disease. Two main biomarkers are used to detect this deposition. 
Firstly,  biochemical  measurements  show  a  decrease  of  the  Aβ1-42 content  in  the
cerebrospinal fluid (CSF)  when the amyloid plaque load is increasing (Palmqvist et al.,
2016). On the other side, increased levels of CSF total (T-tau) and tau phosphorylated at
threonine 181 (P-tau181) are related to the progression of the pathology and correlated with
NFT burden  at  autopsy  (Buerger  et  al.,  2006;  Tapiola  et  al.,  2009). High  diagnostic
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accuracy was shown by the ratio Aβ1-42/P-tau181 demonstrating an added discriminatory
value for AD versus other forms of dementia (Engelborghs et al., 2008). However, CSF
samples must be collected by lumbar puncture which represent an invasive exam.
Secondly, positron emission tomography (PET) is an imaging technique that is able to
detect  the  gamma-rays  pairs  emitted  by  an  injected  radionuclide  synthesized  to  bind
selective molecular targets. Different amyloid tracers (e.g. Pittsburgh compound B [11C]-
PIB (Mathis et al., 2002), [18F]-florbetapir (Wong et al., 2010; Yang et al., 2012) or [18F]-
florbetaben) have  shown exceptional  value  in  the  identification  of  the  Aβ  deposition
(Nordberg et al., 2010).  High correlation of PIB binding and CSF Aβ1-42 level was found
when collected in the same individuals (Fagan et al., 2006). The progresses in radiotracer
development has recently allowed the synthesis of tau PET ligands such  as THK5317,
THK5351,  AV-1451,  and PBB3  (Shah and  Catafau,  2014;  Saint-Aubert  et  al.,  2017).
More  recently  P-tau181 CSF  content  was  associated  with  both  Aβ  and  tau  ligand
measurements but also to cortical thickness (Mielke et al., 2018). 
1.1.3 – Functional and metabolic markers
Although the amyloid hypothesis is  evidenced by numerous experimental and clinical
studies, none of the developed treatments were capable of reducing Aβ plaques or prevent
the disease progression and almost all of the clinical trials proposed have shown small
improvement of the cognitive function  (Franco and Cedazo-Minguez, 2014; Holmes et
al., 2008; Mangialasche et al., 2010). This situation has pushed researchers to develop
diagnostic biomarkers that would enable to investigate the initial events of the disease.
Thus, clarification of the etiological factor(s) and consequences associated with abnormal
cerebral glucose metabolism could provide valuable clues for treatment strategies as well
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as  ideal  diagnostic  approaches  in  AD.  Metabolic  dysfunctions  are  correlated  with the
severity of dementia (Mosconi, 2005). The glucose radioactive analogue called [18F]-FDG
is a PET tracer able to detect synaptic activity (Sokoloff, 1981). Since glucose represent
the  brain  principal  source  of  energy,  its  detection  allows  an  evaluation  of  the  brain
metabolism that has been shown to decrease with the progression of the pathology. A
reduction in the parietotemporal, frontal and posterior cingulate cortex has been found in
patients with AD compared with healthy subjects. [18F]-FDG uptake correlates with post-
mortem histological measurements of the synaptic vesicle protein called synaptophysin
(Rocher et al., 2003). 
Figure 8: From left to right: DMN regions have increased aerobic glycolysis DMN regions in the normal
brain; DMN regions have decreased glucose metabolism in AD; DMN regions are the first to develop
amyloid deposition in AD.  (Sheline and Raichle, 2013)
Moreover, regional analysis, represented in  Figure 8, have shown that in cortical areas
[11C]PIB retention  inversely  correlates  with  glucose  metabolism,  measured with [18F]-
FDG (Y. Li et al., 2008; Mosconi et al., 2010; Oh et al., 2016, p.) possibly indicating an
amyloid toxicity. [18F]-FDG-PET is considered a robust biomarker of neurodegeneration,
observed to be decreased before the onset of cognitive decline in patients who are later
identified to be AD (Jagust, 2006; S. Zhang et al., 2012). However, neurodegeneration is
not specific for AD, and must be integrated with other biomarkers. Moreover, PET is an
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expensive technique limited by the need of specific infrastructures and that require the
exposition to radioactivity. 
Specific  MRI  techniques  have  also  been  developed  to  detect  brain  functional  and
metabolic alterations. With the application of magnetic resonance spectroscopy (MRS)
localized alterations of brain metabolites can be measured. The ratio between N-acetyl-
aspartate and Creatine (NAA/Cr) was found to be significantly reduced in the posterior
cingulate and in the hippocampus of AD patients simultaneously with an increased myo-
inositol (mI)/Cr ratio in posterior cingulate. These indexes were presented as possible AD
biomarkers  (Wang  et  al.,  2015).  Arterial  spin  labeling  (ASL)  is  a  technique  able  to
measure the tissue perfusion trhough the assessment of the cerebral blood flow (CBF)
(Petcharunpaisan et al., 2010). CBF is positively correlated with brain activity (Iadecola,
2004); lower perfusion in patients with MCI and AD was found in the parietal lobe, but
also in angular and middle temporal areas as well as in the left middle occipital lobe and
precuneus  (Alexopoulos  et  al.,  2012).  Functional  MRI  (fMRI)  is  used  to  detect  the
neuronal activity by changes of the blood oxygenation level dependent signal (BOLD)
(Ogawa et al., 1990). Correlating the time courses of the BOLD signal oscillation it is
possible to link brain regions belonging to the same functional network. These networks
can be evaluated in resting conditions or during cognitive tasks to assess the functional
integrity  of  networks  involved  in  memory  and  cognitive  domain.  The  Default  Mode
Network (DMN) comprises different regions that are active in rest condition (Buckner et
al., 2008) including the precuneus/posterior cingulate cortex, medial prefrontal cortex and
the hippocampus (Figure 8). The decreased connectivity found within the DMN of MCI
and AD patients could explain the hypometabolism measured by FDG-PET (Buckner et
al., 2008; Dennis and Thompson, 2014; Sheline and Raichle, 2013). Recently it has been
shown how the anatomical propagation of tau in the AD brain spreads along functional
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networks.  Tau pathology accumulation seems to correlate  with functionally connected
brain regions (Hoenig et al., 2018).
1.1.4 – Structural markers
MRI volumetric measurements can be used to visualize the progressive cerebral atrophy
caused  by  the  overall  neurodegeneration  due  to  dendritic  and  neuronal  loss.  The
enthorinal cortex (Khan et al., 2014) was found to be one of the earliest region of atrophy
followed by the shrinkage of hippocampus,  amygdala and in the end of the temporal
neocortex. This sequence of atrophy progression measured by MRI fits histopathological
studies describing the same regional progression in the spread of NFT (Braak and Braak,
1991; Smith, 2002). Figure 9 shows the evolution of the cortical thickness within a period
of 12 months.
Figure  9:  Cortical  thinning  in  patients.  Measurements  were  performed  between
baseline and 12months. The difference map shows thinning in the range of 0.5mm in
the  medial  temporal  cortex  and  frontal,  parietal  and  temporal  neocortices,  with
relative  sparing  of  the  sensorimotor  strip  and  visual  cortex.  The  thinning  maps
closely with the known progression of neurofibrillary tangles and neurodegeneration
at autopsy. (Frisoni et al., 2010)
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The distribution  and the  rate  of  regional  atrophy were  correlated  also  with  cognitive
impairment  (Cardenas  et  al.,  2011;  Ridha et  al.,  2008).  However,  cerebral  atrophy is
nonspecific for AD and it might be produced by factors different from the progression of
neural loss which should be ideally confirmed by a direct histopathological analysis. 
Although major lesions characterizing AD were identified in the gray matter (GM), it has
been shown that the cognitive impairment can be related to the cortical disconnection
caused  by  the  white  matter  (WM)  degeneration  (Gunning-Dixon  and  Raz,  2000).
Increased levels of Aβ40 and Aβ42 were associated with a decrease in the myelin basic
protein in human WM  (Roher et al., 2002). Factors causing WM degeneration are still
unclear  and  two competing  models  have  been proposed  (Alves  et  al.,  2015):  1) The
retrogenesis model suggest that WM disintegration occurring in AD is at the core of the
earliest changes involved. Myelin breakdown disrupts brain functions with subsequent
loss  of  neurons  and  progression  to  permanent  deficits  (Bartzokis,  2004).  2)  The
alternative hypothesis  which considers the WM degeneration as a consequence of the
Wallerian  degeneration  which  postulates  a  posterior-anterior  gradient  of  fibre
degeneration where the cortical pathology is at the origin of the damage (Coleman, 2005).
Diffusion Tensor Imaging (DTI) is a technique that makes MRI sensitive to the water
diffusion  in  microstuctures.  It  is  therefore  used  to  investigate  WM integrity  showing
abnormalities in corpus callosum, frontal, parietal, temporal cortices of AD patients. The
most  consistent  impairment  was  found in  the  temporal  white  matter  which  is  highly
connected with entorhinal cortex and hippocampus suggesting a relation with the gray
matter neurodegeneration (Acosta-Cabronero and Nestor, 2014; Amlien and Fjell, 2014;
Chua et al., 2008; Stebbins and Murphy, 2009). 
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1.1.5 – AD Transgenic models
Advances in genetic engineering have allowed the creation of transgenic animal models
harboring gene mutations known to cause familiar  AD. Transgenic mice are the most
commonly adopted (Balducci and Forloni, 2011; Hall and Roberson, 2012; Sasaguri et al.,
2017; Esquerda-Canals et al., 2017) but the interest in the use of rat transgenic models is
increasing  (Benedikz  et  al.,  2009;  Do  Carmo  and  Cuello,  2013). The  use  of  these
experimental models offers several advantages; their genome has been entirely mapped,
they can be easily bred and manipulated in order to investigate their cognitive abilities
(Ameen-Ali et al., 2017; Kobayashi and Chen, 2005; Webster et al., 2014). As shown in
Table 1, available experimental models only partially reproduce the AD condition. They
present some of the neuropathological features typical of the human pathology including
cognitive impairment, neuroinflammation and plaque deposition in the brain parenchyma
and in vessels. However, the onset of these features can vary greatly between models and
only few of these present important features like neuronal loss and NFT deposition. A
meta-analysis of 40 peer-reviewed studies that evaluated amyloid deposition in different
transgenic models after  assessing their  cognitive performance found that only a weak
association  exists  (Foley  et  al.,  2015).  Moreover  it  is  difficult  to  model  in  mice  the
complexity of higher-order cognitive functions exclusive to humans. Instead, each mouse
model  allows  the  investigation  of  different  cognitive  dysfunction  related  to  AD.  The
cognitive deficits progression in a specific behavioral task can be quite different among
the mouse models and most of them display deficits in spatial working memory earlier
than the deficits in other cognitive domains (Stewart et al., 2011; Webster et al., 2014).
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Table 1: Most commonly used transgenic models; adapted from (Balducci and Forloni, 2011;
Benedikz et al., 2009; Do Carmo and Cuello, 2013)
Tg Line
 (Reference)
Mutation Cognitive
 Impairments
Neuropathological 
Features
M
ic
e PDAPP
 (Games et al., 
1995)
APP V717F 
(Indiana)
Reference working 
and spatial memory
Aβ plaques (6–9 months), 
dystrophic neurites, gliosis, loss
of synaptic densities
Tg2576
(Hsiao et al., 
1996)
APP 
KM670/671NL
(Swedish)
Reference, working
and recognition 
memory, contextual
memory; 
alternation in Y- 
and T-mazes
Aβ plaques (11–13 months), 
dystrophic neuritis, astrogliosis,
microgliosis
APP23
(Balducci et al., 
2010; Sturchler-
Pierrat et al., 
1997)
APP 
KM670/671NL
(Swedish)
Reference, working
and spatial 
memory; passive 
avoidance; 
recognition 
memory
Aβ plaques (6–12* or 15–18** 
months), cerebrovascular Aβ, 
dystrophic neuritis, neuronal 
loss in CA1 region of 
hippocampus; astrogliosis and 
microgliosis
PS/APP
(Holcomb et al., 
1998)
APP 
KM670/671NL
(Swedish), 
PSEN1 M146L
(A>C)
Reference, working
and spatial 
memory; 
recognition 
memory
Aβ plaques (3–6 months), 
astrogliosis and microgliosis; 
dystrophic neuritis
J20
(Mucke et al., 
2000)
APP 
KM670/671NL
(Swedish), 
APP V717F 
(Indiana)
Reference and 
working and spatial
memory; 
recognition 
memory
Aβ plaques (8 months), gliosis
TgCRND8
(Chishti et al., 
2001)
APP 
KM670/671NL
(Swedish), 
APP V717F 
(Indiana)
Reference, working
and spatial 
memory; 
recognition 
memory
Aβ plaques (3 months), 
astrogliosis and microgliosis; 
dystrophic neuritis
APP/PS1 (or 
APPPS1-21)
(Radde et al., 
2006)
APP 
KM670/671NL
(Swedish), 
PSEN1 L166P
Impaired reversal 
learning in spatial 
maze task at eight 
months of age 
Earlier 
observations of 
cognitive 
impairment shown 
deficits in the 
Morris Water maze 
at seven months of 
age
Aβ deposition (6 weeks). 
Deposits appear in the 
hippocampus, striatum, 
thalamus, and brainstem (4-5 
months). No fibrillar tau 
inclusions are seen. Global 
neuronal loss is not observed, 
but modest neuron loss was 
found in the granule cell layer 
of the dentate gyrus and other 
subregions with high neuron 
density at older ages (17 
months)
ArcAβ
(Knobloch et al., 
APP 
KM670/671NL
(Swedish), 
Cognitive 
impairment at 6 
months of age 
Aβ plaques (6 months)  
affecting both the brain 
parenchyma and vasculature. 
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2007) APP E693G 
(Arctic)
measured by the 
Morris water maze 
and Y-maze 
Plaques are abundant by 9 to 15
months. Develop early deficits 
in synaptic plasticity,  LTP was 
impaired in slices from 3.5 and 
7.5-month-old mice.
P301L
(Lewis et al., 
2000)
MAPT P301L Develop motor 
impairment, with 
90 percent of 
animals exhibiting 
motor and 
behavioral 
problems by ten 
months. 
Neurofibrillary tangles in an 
age and gene-dose dependent 
manner; as early as 4.5 months 
in homozygotes and 6.5 months
in heterozygotes. Neuronal 
loss, especially in the spinal 
cord. Astrogliosis by 10 
months.
APP/PS1/Tau
(Oddo et al., 
2003)
hAPP 695, 
K670N/M671L
(Swedish)
PS1:M146L
Tau: P301L
Progressive age-
related memory 
impairment (4 
months) correlated 
with intraneuronal 
Aβ
3–4 months: intracellular Aβ 
accumulation in the neocortex; 
6 months: intracellular Aβ 
accumulation in the CA1 region
of the hippocampus;
12 months: extracellular Aβ 
deposition in cortex and 
hippocampus;
12 months: NFTs appearance in
the hippocampus
TASTPM
(Howlett et al., 
2004)
APP 
KM670/671NL
(Swedish), 
PSEN1 
M146V
Age-dependent 
impairment in 
object recognition 
memory (6 
months). 
Aβ plaques (3–6 months), 
astrogliosis and microgliosis; 
localized neuronal cell loss
5XFAD
(Oakley et al., 
2006)
APP 
KM670/671NL
(Swedish), 
APP I716V 
(Florida), APP 
V717I 
(London), 
PSEN1 M146L
(A>C), PSEN1
L286V
Impaired spatial 
memory (4-5 
months)
Impaired stress-
related memory (6 
months).
Impaired remote 
memory 
stabilization (4 
months).
Gliosis (2 months) in parallel 
with plaque deposition.
Synapse degeneration (4 
months) as well as neuronal 
loss.
APPNL-G-F
(Saito et al., 2014)
APP 
KM670/671NL
(Swedish), 
APP I716F 
(Iberian), APP 
E693G 
(Arctic)
Memory 
impairment in 
homozygous mice  
(6 months).
Aggressive amyloidosis (2 
months) with near saturation by
7 months.  
Aβ deposition at 4 months in 
heterozygous mice. 
Microgliosis and astrogliosis 
(2months). 
Reduction of synaptophysin 
associated with Aβ plaques.
Absent neural loss.
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R
at
s TgAPPswe
(Ruiz-Opazo et 
al., 2004)
APPswe
(Swedish)
Attenuated memory
decline;
Increased APP mRNA (56%) 
and Aβ-40 and Aβ-42 peptides
No plaques
UKUR25
(Echeverria et al., 
2004)
hAPP751
(Swedish)
Mild impairment 
(16 months)
No plaques
Tg6590
(Folkesson et al., 
2007)
APPswe
(Swedish)
Impairment in 
morris water maze 
(9 months)
Rare diffuse Aβ plaques;
Increased tau phosphorylation
PSAPP
Tg478/Tg1116/Tg
11587
(Flood et al., 
2009)
APP695 Swe
APPswe/ind
hPS1 Finn
Starting from 7 
months
Mostly diffuse plaques Few 
compact plaques in 
hippocampus. 
No vascular Aβ deposits;
Astrogliosis and microgliosis.
No neuronal loss
McGill-R-Thy1-
APP
(Leon et al., 2010)
hAPP751 
(Swedish)
Progressive 
learning deficits.
Aβ plaques (6-9 months.)
Dystrophic neurites and 
astrogliosis around plaques
TgF344-AD
(Cohen et al., 
2013; Pentkowski 
et al., 2018)
hAPP695 
(Swedish)
PS1ΔE9
Increased anxiety-
like behavior 
without significant 
deficits in the 
spatial memory
Progressive Aβ deposition.
Tau hyperphosphorylation and 
neurofibrillary tangles.
Gliosis, apoptotic loss of 
neurons in the cerebral cortex 
and hippocampus.
Technological  progress  has  allowed  the  translation  of  MRI  and  PET  imaging
investigations  to  experimental  models.  However,  as  shown  in  table  Table  2,  results
obtained are still insufficient and unclear, showing a high dependence on the transgenic
line  studied  as  a  consequence of  the  complex spectrum of  neuropathological  features
presented by these models.
Brain structural modifications of these transgenic models have been investigated through
high resolution structural  MRI showing that  atrophy is  difficult  to identify.  Structural
alterations  are  not  always  present  or  are  not extensive  enough  to  affect  the  whole
structures. Moreover, atrophy involves brain regions that aren’t affected in AD patients,
predicting the locations of amyloid formations at later stages. Similarities between the
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outcomes  of  humans  and  rodents  DTI  studies  were  described.  The  use  of  transgenic
models  gave  also  the  opportunity  to  demonstrate  that  fibrillar  amyloid  deposits  and
associated gliosis in brains of aged transgenic mice are accompanied by a reduction in the
apparent diffusion coefficient  (Mueggler et al., 2004).
Metabolic alterations similar to those described in humans were observed with MRS in
transgenic  models,  although  these  were  mostly  found in  aged  mice  (Mlynárik  et  al.,
2012). Recent studies have also shown how such metabolic alterations can be detected
also through the chemical exchange saturation transfer (CEST) MRI (van Zijl and Yadav,
2011). This technique exploits the natural exchange of hydrogen’s atoms between water
and  its  surrounding  molecules.  By  the  application  of  a  saturation  pulse  before  the
acquisition, the intensity of CEST images can be modulated depending on the metabolite
concentration  in  the  tissue.  With  this  approach it  was  possible  to  create  maps  of  the
glutamate (Crescenzi et al., 2016; Haris et al., 2013a) or the myo-inositol content (Haris
et al., 2013b) in the brain of transgenic mice and therefore to detect alterations in their
concentration, allowing researchers to overcome the resolution limit typical of the MRS
technique.
As shown in Table 2, [18F]-FDG PET studies have shown a huge variability of the glucose
brain metabolism between transgenic models at different ages. These variations might be
related  not  only  to  the  intrinsic  complexity  of  the  transgenic  models  but  also to
differences  in  microPET  acquisition  parameters  and  environmental  factors  (e.g.
temperature, fasting time, stress level) during the experiments. These factors could reduce
sensitivity  and  affect  mouse  metabolism  adding  variability  between  different  studies
(Kuntner et al., 2009; Deleye et al., 2016). Different PET radioligands were also recently
developed  to  detect  activated  microglia  showing  a  correlation  with  Aβ  formation  or
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showing that its deposition is preceded by astrogliosis  (Matthias Brendel et  al.,  2016;
Donat et al., 2018).
CBF and resting state fMRI studies with transgenic models confirmed results obtained in
humans. Although in few cases no difference between transgenic models and wild type
mice  was  detected.  Hypoperfusion  and  deficits  in  functional  connectivity  of  the
hippocampus and/or  cortex were described but  an important  considerations  should be
done:  a  great  care must  be taken in  the  choice  of  the anesthesia  because  it  plays  an
important role in the modulation of brain networks. Moreover, many studies in patients
are carried out with task-based fMRI which is not feasible in rodent making impossible
the investigation of specific brain circuits.
Different class of MRI contrast agents were synthesized to bind  Aβ plaques. Some of
these have never been tested in patients but only in transgenic models. Aβ was labeled
with chelated forms of gadolinium (GdDTPA) or iron-oxide nanoparticles trying to create
respectively hyper or hypo-intense spots in correspondence of the plaques (Dudeffant et
al., 2017; Poduslo et al., 2002; Sigurdsson et al., 2008; Wadghiri et al., 2003). Similarly,
MRI contrast agents were also developed labeling with 19F existing molecules used for
ex-vivo  amyloid  staining.  By  MRI  sequences  sensitive  to  T2*  changes,  it  was  also
possible to visualize the plaque load without the need of esogenous agents but using the
contrast arising from the iron content within the plaques. [11C]-PIB has been widely used
both in humans and experimental models showing that its binding to Aβ deposits is highly
dependent  on  the  transgenic  model  adopted  and  to  the  structure  of  the  Aβ  plaques.
Different tau radioligands were also developed with the help of transgenic models and
recently translated to patients (Shah and Catafau, 2014).
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Table 2: MRI and PET methods applied to transgenic models.
Method Tg Line Outcomes (References)
M
R
I Structural MRI PDAPP Severe atrophy of the medial and temporal lobe
with a focus in the hippocampus (8-12-24 
months) (Gonzalez-Lima et al., 2001; Weiss et 
al., 2002; Redwine et al., 2003; Valla et al., 
2006)
APP/PS1 Atrophy identified in the midbrain area and 
not, as expected, at isocortical/hippocampal 
levels.  The severity of brain atrophy in aged 
mice was not correlated with the extent of 
cerebral amyloidosis (Delatour et al., 2006; 
Lau et al., 2008)
TASTPM
APP/PS2/Tau
Hippocampal atrophy was found in TG mice. 
In APP/PS2/Tau the effect was age-dependent, 
whereas in TASTPM it was detectable from the
first investigated time point. Both mice 
displayed an age-related entorhinal cortex 
thinning and robust striatal atrophy. (Micotti et 
al., 2015)
J20 Increased regional cortical thickness in young 
TG mice relative to age-matched WT mice. 
However, the transgenic mice shown a greater 
rate of cortical thinning over 15 months. 
(Grand’maison et al., 2013; Hébert et al., 2013)
PS2APP Do not present volumetric difference in whole 
brain and ventricles (von Kienlin et al., 2005)
DTI APP23 Aβ deposits and associated gliosis of TG mice 
are accompanied by a reduction in the apparent
diffusion coefficient at 24 months. (Mueggler 
et al., 2004)
PDAPP No differences in young mice. Significantly 
decreased FA and increased MD in PDAPP 
mice compared to WT mice at 15 months. 
(Song et al., 2004)
APP/PS1 Changes in water diffusion parallel and 
perpendicular to axonal tracts in corpus 
callosum, fimbria of the hippocampus. A 
significant increase in diffusivity was found in 
specific hippocampal subregions correlate with
neural loss. (Shu et al., 2013, p. 1; Zerbi et al., 
2013)
Tg2576 Reduction in MD and AD were observed in 
gray and white matter starting from 12 months 
age in transgenic mice. (Sun et al., 2005)
MRS Tg2576
5xFAD
TASTPM
Altered metabolites content were detected 
mostly in aged mice, in frontal cortex, 
hippocampus and striatum (Mlynárik et al., 
2012; Nilsen et al., 2012; Forster et al., 2013; 
29
APP/PS1
McGill-R-Thy1-
APP
Micotti et al., 2015):
- Decreased levels of N-acetyl-aspartate, 
glutamate and GABA 
- Increased levels of Myo-inositol
CEST APP/PS1
PS19
Metabolite high resolution imaging highlighted
differences between WT and TG mice: 
- Decreased of glutamate levels. (Haris et al., 
2013a; Crescenzi et al., 2014, 2016) 
- Increased Myo-inositol (Haris et al., 2013b)
rsfMRI APP/PS1
ArcAβ
PS/APP
McGill-R-Thy1-
APP
Reduced functional connectivity both in mice 
and rats models. (Shah et al., 2013; Grandjean 
et al., 2016; Parent et al., 2017; Wiesmann et 
al., 2017)
E22ΔAβ No differences. (Grandjean et al., 2016)
Tg2576 Increased connectivity in hippocampal and 
cortical networks prior to amyloid plaque 
formation. Decreased connectivity in those 
areas after plaque formation.(Shah et al., 2016)
APPNL Decreased connectivity between the prefrontal 
cortex and hippocampus, relative to APPNL-G-F 
mice, at 3 months, but not at 7 or 11 months.
(Latif-Hernandez et al., 2017)
APPNL-GL-F Increased connectivity between the prefrontal 
cortex and hippocampus, relative to APPNL 
mice, at 3 months, but not at 7 or 11 months.
(Latif-Hernandez et al., 2017)
rCBF APP23
ArcAβ
J20
Hypoperfusion in old mice (Hébert et al., 2013;
Maier et al., 2014, 2015, p. 23; Wiesmann et 
al., 2015; Sierra-Marcos, 2017; Ni et al., 2018)
Gd-enhanced 
plaque imaging 
APP/PS1
APP23
APPSwDI
3xTg
Tg2576
Paramagnetic labeling with a chelated form of 
gadolinium (GdDTPA) (Poduslo et al., 2002; 
Wadghiri et al., 2003; Sigurdsson et al., 2008; 
Dudeffant et al., 2017)
Susceptibility-
enhanced plaque 
imaging
APP/PS1
Tg2576
APP[V717I]
APP23;
APP23xPS45 
- Iron-oxide nanoparticles were used for 
magnetic labeling of Aβ deposits.(Beckmann et
al., 2011; Yang et al., 2011; Wadghiri et al., 
2013)
- T2* sensitive sequences without contrast 
agents using the contrast arising from the iron 
content within the plaques (Jack et al., 2004, 
2005; G et al., n.d.; Braakman et al., 2006; 
Maier et al., 2015)
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Measure of T1 and 
T2 relaxation times
APP/PS1 Compared to WT mice, the T2 values in 
younger AD mice were significantly greater, 
while the T2 values in older AD mice were 
significantly less. (Li et al., 2016)
TASTPM T1 /T2 values were shorter overall in TG mice,
indicating possible differences in water 
content. (Forster et al., 2013)
PS/APP The T2 was significantly reduced in the 
hippocampus, cingulate, and retrosplenial 
cortex, but not the corpus callosum, of TG 
mice. No differences in T1 values or proton 
density were detected (16-23 months).(Helpern
et al., 2004)
Tg2576 Decrease in T2 in the cortex, hippocampus at 
16 and 18 months of age. (Braakman et al., 
2006)
Fluorine-19 
amyloid detection
Tg2576
APP/PS1
APP23
Amyloid deposition detected in elderly mice 
with curcumin and styrylbenzoxazole 
derivated.(Higuchi et al., 2005; Okamura et al.,
2004, 2004; Yanagisawa et al., 2014; Tooyama 
et al., 2016)
PE
T Glucose metabolism
[18F]-FDG 
APP23 No differences detected at 13 months age 
(Heneka et al., 2006)
APP/PS1 Hypermetabolism starting from 12 months 
(Poisnel et al., 2012, p. 1)
Tg2576 Hypermetabolism at 7 months but it normalizes
with age. (Luo et al., 2012)
TASTPM Hypometabolism starting from 9 months 
(Deleye et al., 2016; Waldron et al., 2017, p. 
45, 2015c)
APPPS1-21 Hypometabolism (12-13 months)(Waldron et 
al., 2015b; Takkinen et al., 2016)
5xFAD Hypometabolism (13 months) (Macdonald et 
al., 2014)
McGill-R-Thy1-
APP
Hypometabolism (16-19 months)(Parent et al., 
2017)
Amyloid plaques APP23
Tg2576
APP/PS1
APPPS1-21
- [11C]PIB binding to Aβ deposits is highly 
dependent on the Tg model and the structure of
its Aβ plaques. (Snellman et al., 2013). An 
inverse relationship between [11C]PIB and 
rCBF MR imaging was observed in APP23 
mice. (Maier et al., 2015, 2014)
- [18F]flutemetamol and [18F]florbetaben 
retention were also detected to be increased in 
aged mice. (Snellman et al., 2014, 2012; 
Waldron et al., 2015a)
Tau pathology P301S [18F]THK5117 accumulation correlated with 
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GSK-3b·Tau-
P301L
immunhistochemical tau loads in aged mice 
(M. Brendel et al., 2016)
PS19 In vivo optical and PET imaging demonstrated 
sensitive detection of tau inclusions by 
[11C]PBB3. (Maruyama et al., 2013)
TauP301L [18F]THK523 shown high affinity and 
selectivity for tau pathology both in vitro and 
in vivo. (Fodero-Tavoletti et al., 2011, p. 523)
Microglial 
activation
5xFAD The mitochondrial translocator protein TSPO 
tracer [11C]PBR28 provides an accurate 
visualization and quantification of changes in 
microglial density. (Donat et al., 2018)
PS2/APP Positive correlation between the TSPO tracer 
[18F]GE180 of microglial activation and 
amyloid load measured with [18F]florbetaben 
and likewise with metabolism measured with 
[18F]-FDG. (Matthias Brendel et al., 2016)
Astroglial  
activation
APPswe Cortical and hippocampal [11C]DED PET 
binding was significantly higher at 6 months 
than at 8-15 months or 18-24 months preceding
amyloid plaque deposition. (Olsen et al., 2018; 
Rodriguez-Vieitez et al., 2015)
Despite this complex scenario, studying transgenic models has still a great value. Such
models  allow the  isolation  of  the  contribution  of  a  single  pathological  change to  the
disease  progression.  Their  translational  power  is  boosted  by  the  opportunity  for  the
application of imaging techniques used to diagnose AD in humans, owing to similarities
in acquisition  parameters  and outcomes.  The use of  such imaging techniques  permits
longitudinal and non-invasive investigations reducing the number of animals needed in
research studies. Potential imaging biomarkers identified in animal models can suggest
targets for the intervention in humans. Equally,  findings in human studies can suggest
targets for multi-modal studies in transgenic models.  These data can be integrated with
invasive  techniques  not  feasible  in  humans,  such  as  high  resolution  multi-photon
microscopy  or  electrophysiology,  creating  a  virtual  link  between  micro  and  macro-
structures and providing new insight into the observed alterations. 
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1.2 – Magnetic Resonance Imaging
Within  this  section  I  will  give  a  brief  overview  of  the  MRI  technique.  Rather  than
describing in detail the spatial encoding process behind the formation of an MRI image,
the attention will be focused on the introduction of the MRI signal. By explaining how
each MRI technique manipulates the signal it will be  possible to describe the principal
acquisition parameters that will be found in the chapters describing methods and results.
For a complete quantum mechanical description please refer to chapters 3-6 of the book
entitled  “Magnetic  Resonance  Imaging  –  Physical  principles  and  Sequence  Design”
(Brown et al., 2014).
1.2.1 – MRI signal
MRI imaging takes advantage of the atom’s magnetic properties. The nucleus of an atom
is formed by protons and neutrons and it is characterized by the so called total angular
momentum  otherwise  known  as  nuclear  spin.  Atoms  with  even  atomic  number  are
unaffected by external magnetic fields, on the contrary nuclei with half-integer spin (such
as  1H,  17O,  19F,  23Na or  31P) have a characteristic magnetic behavior. Due to its natural
abundance  in  biological  tissues,  the  hydrogen  atom  can  be  detected  by  magnetic
resonance techniques.  It is formed by a single proton and a single electron orbiting the
nucleus. Hydrogen nuclei behavior in a magnetic field is very similar to the needle of a
compass in presence of the external earth’s magnetic field. Similarly, hydrogen nuclei are
oriented in a random manner and the sum of all their magnetic moments has a zero value,
but when immersed in the static magnetic field of the MRI scanner they point along it’s
principal direction. Experiencing both the effect of the MRI and the earth magnetic fields,
all protons starts precessing (Figure 10c) around the direction of the main MRI magnetic
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field, yielding to a non zero net magnetization. The angular frequency of the precession,
called Larmor frequency ω0, depends on the strength of the applied magnetic field B0,
according to the equation:
ω0=γB0  [1]
where γ is a constant called the gyromagnetic ratio, whose value is characteristic for the
nucleus of interest.
Figure 10: Spin orientation in absence (a) and in presence (b) of an external magnetic field. M z is the net
magnetization representing the contribution of all spins. c) Precessional motion of a spin.
As shown in Figure 11, some energy can be introduced when an external electromagnetic
wave (B1) with an orientation of 90° respect to the direction of the main magnetic field
and characterized by a frequency equal to the Larmor frequency is applied.
Figure 11: Net magnetization a) under normal conditions and b) after the effect of the
external electromagnetic wave. 
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All the longitudinal magnetized spins are reversed in the transverse xy-plane, resulting in
a net magnetization that is now denoted as Mxy rather than Mz. This magnetization rapidly
fades  out  due  to  two  independent  processes.  Once  that  the  magnetization  has  been
reversed, the spins start preceeding with different phases due to the spin-spin interaction
(Figure 12)  causing  the so called T2 relaxation of  the  signal.  The T2* decay is  also
described in medical imaging and it’s due to additional field inhomogeneities contributing
to the dephasing process. T2 decay is more or less independent of the strength of the
external magnetic field (B0) and it is in the range of 40-300ms.
Figure 12: Relaxation process. Spins reversed in the transverse plane start preceding around
the main direction of the magnetic field causing. The sum of these spins (MXY) decrease with
a time called T2 relaxation time.
While the transverse magnetization (MXY) decays the magnetic moments gradually realign
with  the  z-axis  of  the  main  magnetic  field  (B0) following  the  so  called  spin-lattice
interaction  process  that  reflects  the  interaction  of  nuclei  with  their  molecular
surroundings,  and  how quickly  the  energy  can  be  transferred  from the  nuclei  to  the
environment.  This process is regulated by the T1 relaxation recovery time which is in the
range of 0.5-3sec (Figure 13).
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Figure 13: Relaxation recovery process. Relaxation process. Once the effect of external 90° RF
pulse end,  spins reversed in the transverse plane start recovering their original magnetization
(MZ) with a recovery time called T1.
Since the oscillating spins are charged particles moving in a magnetic field, currents can
be induced in conductor coils making the detection feasible. The detected signal is known
as free induction decay (FID) and it is proportional to the number of excited nuclei in the
tissue  and  it  lasts  as  long  as  there  is  a  transverse  component  (MXY)  of  the  net
magnetization vector.
Figure  14:  Left:  Temporal  evolution  of  the  net  Magnetization.  Right:  Free  Induction  Decay
obtained by reading the transverse magnetization.
While the T1 is few order of magnitude longer than the T2 relaxation time, the transverse
magnetization can be recovered by applying a further 180° electromagnetic pulse (Figure
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15). The spins’ rotation is reverted obtaining their refocusing in the transverse plane and
the recovering of the transverse magnetization. 
A second class  of  detectable  signal  called “echo”  is  then produced (Error:  Reference
source not found). 
  
Figure 16: Spin-echo sequence.
A series of echoes caused by a train of consecutive 180° RF pulses can be obtained and
detected. The amplitudes of the echoes diminishes with the T2 (Figure 17). 
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Figure 15: Spin refocusing with a 180° EM pulse.
Figure 17: Generation of a series of echoes using a train of consecutive 180° pulses, following. TR is
the time between 90° pulses.
1.2.2 – T1 and T2 mapping
When an MRI image is generated, the acquisition parameters TR and TE can be chosen in
order to emphasize it’s contrast properties. The signal, S, in a spin-echo sequence could
be described by:
S∝ρ⋅[1−exp(− TRT 1 )]⋅exp(− TET 2 )   [2]
Where  ρ  is  the  spin  density,  and  represents  the  number  of  protons  per  unit  volume.
Indicating that  altering the TR and TE acquisition parameters  an effect  on the image
contrast will be dependent by the T1 or T2 of the tissues (Figure 18). Increasing the TR
period  the  T1  information  of  the  image  increases  resulting  in  a  modulation  of  the
gray/white matter contrast but CSF remains dark. On the other hand, by shortening the TE
the CSF is characterized by a small signal. For intermediate TE the overall contrast is
poor but at long TE a large signal, resulting in a bright area, for the CSF can be obtained. 
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Figure 18: Simulation that shows how tissues intensities can be modulated varying TR and TE (panel b
adapted from (Dowsett, 2006)). 
The so called T1-weighted or T2-weighted images can be used to evaluate the volume
alterations of different brain regions that are typical of the AD pathology. Moreover, the
T1  and  T2  tissues  times  can  be  measured  by  acquiring  a  series  of  images  with
respectively  fixed  TR  and  varying  TE  or  varying  TR  and  fixed  TE.  The  equations
describing the signal evolution can be derived from the equation 2:
S∝[exp(− TE
T 2
)]  [3]
S∝[1−exp (−TR
T 1
)]  [4]
Pathological alteration of the tissue composition can alter T1 and T2 measurements. An
accumulation of lipids or iron leads to a reduction of the measured T1 when compared to
healthy tissue. An increase of the water (e.g. edema) has the consequence of altering both
relaxation times but is more pronounced in T2 sensitive measurements (Puntmann et al.,
2016). Similarly the formation of NFT and amyloid plaques, resulting in cell loss are
expected to alter relaxation times by altering the biochemical environment of the tissue.
The in-vivo evaluation of the T2 time have shown differences between transgenic and
age-matched wild type mice (see table Table 2).
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1.2.3 – Magnetic Resonance Spectroscopy
The magnetic resonance spectroscopy technique is able to investigate the concentration of
different chemical species in a selected volume. To explain its operating principle, the
concept explained with equation 1 must be further elaborated. When an atom is placed in
a magnetic field its orbiting electrons causes a small magnetic field which opposes the
externally applied field. The effective magnetic field at the nucleus is generally less than
the applied field by a fraction σ and described by:
B=B0(1−σ) [5]
The electron density around each nucleus in a molecule varies according to the types of
nuclei and bonds in the molecule leading to different emission frequency associated with
it.  This  is  called  the  'chemical  shift'  phenomenon  that  provides  a  mechanism  for
separating the signal contribution of chemically different nuclei. However, because of the
high water concentration in biological tissues, the MR signal is dominated by its protons
making the contribution of other chemical species negligible. To overcome this issue a
saturation pulse is added to the sequence in order to suppress the water contribution of
water  to  the signal  (Griffey and P.  Flamig,  1990).  The Point  RESolved Spectroscopy
(PRESS) sequence is the most commonly used spectroscopy method. It consists of three
slice-selective RF-pulses (90º−180º−180º) applied with three orthogonal gradients (x, y
and z). The signal at time TE is derived only from protons located in a voxel where the
three imaging planes overlap (Figure 19). 
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Figure 19: PRESS MRS sequence.
The acquired signal is called ‘spectrum’ and it can be considered as the summation of
each metabolite contribution (Figure 20). The principal metabolites detectable in the brain
are:
• N-acetyl-Aspartate (NAA).  The  largest  peak  in  the  spectrum,  located  around 2
p.p.m. It is an amino-acid derivative synthesized in neurons and transported along
axons. It is therefore considered an index of neural and axonal integrity. NAA plays
a diagnostic role in brain tumors, head injury and dementias. 
• Creatine (Cr) is a peak, located at 3.03 p.p.m. It is composed by the contribution of
both creatine and phospocreatine that are involved in the energy metabolism.
• Choline (Cho)  is  located  at  3.22  p.p.m.  It  represents  the  sum  of  choline  and
phosphocholine contributions. Since these are involoved into phospolipids syntesis
and  degradation  process,  Cho  is  considered  as  a  marker  of  cellular  membrane
turnover. 
• Myo-inositol (mI)  is  assigned  at  3.56  p.p.m.  Increased  mI  contents  has  been
associated with astroglial activation. It’s increase has been observed in AD patients.
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• Glutamate (Glu) and Glutamine (Glm). Since these are difficult to be differentiated
are  often  considered  as  a  unique  peak  called  Glx  and  located  at  2.05  p.p.m.
Glutamate is a excitatory neurotrasmitter involved in the redox cycle. 
Figure  20:  Quantification of 16 neuro-metabolite  signals  from in
vivo  1H-MRS  in  the  right  dorsal  hippocampal  region  of  a  rat.
Adapted from (Lee et al., 2016)
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1.2.4 – Chemical Exchange Saturation Transfer
MR spectroscopy is a technique that suffers with certain limitations. Physiological and
non-physiological motion may causes an increased of the acquired line widths, shifts of
the overall frequency, reduced peak areas, and decreased quality of water suppression. Al
of these may lead to signal degradation resulting noisy spectra that may be not acquired in
small portion of the brain. To overcome these limitation the chemical exchange saturation
transfer  (CEST) technique may be helpful  allowing the indirect  detection of different
chemical species.  CEST technique takes advantage of the natural exchange of protons
between  water  and  its  surrounding  molecules.  Since  the  MRI  image  is  obtained  by
acquiring the water’s protons signal, its intensity can be modulated with the application of
a selective saturation pulse just before its acquisition. 
Figure 21: Pulse sequence diagram. (Dula et al., n.d.)
The solute protons belonging to CEST agents have frequency of resonance different than
the water. Consequently, if the RF pulse is able to selectively saturate these protons, when
they exchange with water they won’t contribute anymore to the overall signal resulting in
decreased intensity of the image. The so-called Z-spectrum is generated by measuring the
normalized water saturation (Ssat/S0) as a function of irradiation frequency. The minimum
intensity  of  the  Z-spectrum,  represented  as  0  p.p.m,  is  obtained  by  saturating  at  the
water’s frequency of resonance. With the analysis of the Z-spectrum asymmetry, called
Magnetization Transfer Ratio (MTR = 1 –  Ssat/S0), information about the CEST agents
content can be obtained. However, the magnitude of the MTR asymmetry depends on
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different factors affected by the physiological conditions (concentration, temperature, pH,
spectral  position of the protons and relaxation times of protons involved) but also by
experimental parameters (intensity and duration and homogeneity of the RF pulse but also
the homogeneity of the static magnetic field B0).
Figure  22:  Chemical  Exchange  Saturation Transfer  (CEST):
principles and measurement approach.(van Zijl and Yadav, 2011)
As long as the RF pulse is active the effect can become visible thanks to the continuous
transfer  of  the  saturation.  To successfully  generate  a  CEST contrast  the frequency of
resonance gap between the CEST agent and the water (expressed in rads/sec) must be
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bigger than their exchange rate  (Soesbe et al., 2013; Ward et al., 2000). Therefore with
high magnetic field strengths an increased frequency of separation allows the imaging of
CEST agents with faster exchange rate. The effect of the magnetic field is amplified also
by the  slower  recovery  of  the  magnetization  that  produce  longer  T1 relaxation  times
resulting in larger CEST contrast.
Table  3: MR properties for CEST imaging of the mouse cortex at different B0
field strengths.(G. Liu et al., 2013)
B0
(Tesla)
Frequency separation (Hz) per 1 ppm T1 (ms) T2 (ms)
2.35 100 1010 68.5
4 170 1286 65.2
4.7 200 1315 54.6
9.4 400 1948 42.1
11.7 500 2073 36.2
17.6 750 2030 30
Different  class  of  CEST  agents  have  been  investigated  and  separated  in  two  main
categories. The paramagnetic CEST (paraCEST) agents are molecules containing metallic
ions which can be visualized far away from water resonance if compared to the second
class called diamagnetic CEST (diaCEST) agents that usually have Z-spectrum comprised
within 6p.p.m from water. ParaCEST are usually exogenous molecules that need to be
injected and their use could be associated with toxicity due to their metal content. As
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Figure 23: Numerical simulation of B0 field dispersion influences on CEST contrast in the mouse cortex
using the Bloch equations: a) z spectra, b) MTRasym plots, and c) peak CEST values plotted against the
B0 field with the proton exchange rate ranging from 30 Hz to 1000 Hz. (G. Liu et al., 2013)
shown in table Table 4, diaCEST agents could be endogenous molecules containing three
class of exchangeable groups. 
Table 4: CEST Exchange properties for endogenous molecules (Kogan et al., 2013)
Amide protons
(-NH)
Amine protons 
(-NH2)
Hydroxyl protons
(-OH)
Chemical Shift 3.5 p.p.m. 1.8-3.0 p.p.m. 0.5 – 1.5 p.p.m.
Exchange Rate 
(ksw) Range 10-100 s
−1 > 500 s−1 500-1500 s−1
Endogenous 
Metabolite
Multiple 
Unknown
Glutamate (Glu),
Creatine (Cr)
Glycosaminoglycans
(GAG), Glycogen, 
Myo-Inositol (MI), 
Glucose
CESTasym 1-4 % 7-10% 2-8%
Sensitivity to pH Yes Yes Yes
CEST 
Applications Cancer/Stroke
Skeletal Muscle 
and Myocardial 
Muscle Energetics,
Cancer 
Metabolism (Cr), 
Neuropsychiatric 
Disorders (Glu)
Osteoarthritis 
(GAG), Neurological
Disorders (MI), 
Cancer Metabolism 
(Glucose)
AmideCEST,  often reported as amide proton transfer  (APT),  was firstly  described in
rodents showing that it can be used to produce a pH weighted images in stroke (Zhou et
al., 2003b) and tumor models (Zhou et al., 2003a). Thanks to the amides slow exchange
rate, APT is not limited by the strength of the magnetic field and it has been consequently
translated to the clinical context (Zhou, 2011). 
AmineCEST has been used to create spatial maps of the glutamate and creatine content
in the brain and thus referred respectively as GluCEST  (Cai et  al.,  2012) or CrCEST
(Kogan  et  al.,  2014a,  2014b;  Cai  et  al.,  2017).  GluCEST  measurements  shown
significantly decreased levels of glutamate in mouse models of middle cerebral artery
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occlusion  (MCAO)  (Cai  et  al.,  2012) and  stroke  (Zaiss  et  al.,  n.d.) but  also  to
neurodegenerative disorders mouse models of AD (Bagga et al., 2016; Crescenzi et al.,
2016, 2014; Haris et al., 2013a) and Huntington disease  (Pépin et al., 2016) GluCEST
spatial  distribution was verified using PET maps of the glutamate receptor  subtype 5
(Ametamey et al., 2007) and its reproducibility demonstrated in humans  (Nanga et al.,
n.d.). When applied to  individuals with a psychosis spectrum it was also able to show
abnormal levels of glutamate when compared with healthy subjects (Roalf et al., 2017)
The chemical  exchange of  hydroxyl groups is  characterized by a  high exchange rate
corresponding to a region of interest in the Z-spectrum which is the closer one to the
water  frequency  of  resonance  among  all  the  diaCEST agents.  This  makes  the  CEST
imaging of hydroxyl protons feasible only with high fields MRI scanner (> 7T). Different
metabolites have been mapped with this technique such as glycosaminoglycan (GAG) or
myo-inositol  or  glucose  and  in  the  same  fashion  of  other  CEST  agents  it  may  be
respectively  called  as  GagCEST,  MICEST  or  GlucoCEST.  Since  a  non-uniform
distribution of mI was shown in early stages of AD and related to dysfunctional glial cells
(von Bernhardi, 2007), MICEST was presented as a potential biomarker showing showing
that elevated levels of mI can be measured in AD transgenic models (Haris et al., 2013b).
Due to its  limited concentration,  a  direct  mapping of endogenous glucose is  difficult.
However, as shown in Figure 24, the injection of D-glucose has been proposed as MRI
contrast agent alternative to [18F]FDG-PET in the identification of tumor regions that are
characterized by an altered metabolic consumption  (Rivlin et al.,  2014, 2013; Walker-
Samuel et al., 2013).  Results in cancer research with animal models and [18F]FDG-PET
have been duplicated with different molecules homologue to D-glucose as the 2-deoxy-D-
glucose (2DG) (Rivlin et al., 2013), 3-O-methy-D-glucose (3OMG) (Rivlin et al., 2014)
and 2-amino-2-deoxy-D-glucose (GlcN) (Rivlin and Navon, 2016). The feasibility of this
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approach has been recently shown also in human studies (Paech et al., 2017; Schuenke et
al., 2017). Similar studies have demonstrated that the uptake of D-glucose can be detected
in the brain of healthy rats (Nasrallah et al., 2013). However, due to its fast metabolism in
the  brain  the  D-glucose  CEST  signal  rapidly  fade  out.  2DG  was  proposed  as  an
alternative  to  D-glucose  to  detect  brain  metabolism since  it  enters  cells  by the  same
transporters but it does not go into glycolysis. 2DG is only phosphorylated by hexokinase
into  2DG-6-phosphate  (2DG6P)  and  trapped  in  cells  for  many  hours  because  it’s
minimally metabolized (Jin et al., 2016). 
Figure  24: (a) Comparison of tumor glucose uptake measured with glucoCEST and [18F]FDG
autoradiography in two human colorectal tumor xenograft models (SW1222 and LS174T). The
fluorescence  microscopy  images  show  perfused  (blue)  and  hypoxic  regions  (green)
corresponding to Hoechst 33342 and pimonidazole staining, respectively. (b) and (c) Show that
the uptake of both glucose and FDG was significantly different between tumor types (*, P < 0.01,
Mann-Whitney).  (d)  Scatter  plot  of  median  tumor  [18F]FDG  and  glucoCEST enhancement,
which shows a significant correlation (P < 0.01, Spearman’s rho). Adapted from (Walker-Samuel
et al., 2013)
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1.2.5 – Diffusion Tensor Imaging
As previously mentioned, the principle underlying DTI imaging is the water molecules
diffusion.  In  1905 Albert  Einstein  was  the  first  to  describe  that  the  particles  random
movement in a liquid is governed by their thermal energy and thus it can be described
with a diffusion coefficient (D) (Einstein, 1905). 
As shown in Figure 25,  water molecules motility can influence the process regulating the
magnetization recovery  and thus  the MRI signal.  This  influence  can  be  measured  by
slightly  modifying the spin-echo pulse sequencing by adding a  field  gradient  module
(characterized by the diffusion weighting a factor) just before the 180° degree pulse. A
magnetic field gradient can be described as variation of the magnetic field along one
spatial direction. Once that the 90° pulse has been applied protons start dephasing around
the main direction of the magnetic field. The amount of this dephasing is proportional to
the diffusion distance covered by water molecules during the gradient pulse. The effect of
this “dephasing” is a reduction of the MRI signal amplitudes. The equation 2 describing
the MRI signal could be than extended as: 
S=ρ⋅[1−exp(−TRT 1 )]⋅exp(−TET 2 )⋅exp(−b⋅D)  [6]
Where b is the diffusion weighting factor  and D is the diffusion coefficient. In regions
with fast water diffusion (e.g. CSF), the signal is reduced more when compared to the
signal  reduction of areas with slow water  diffusion (e.g.  white  matter).  The so-called
apparent  diffusion  coefficient  (ADC) map  is  can  be  created  by  acquiring  a  series  of
images with fixed TR and TE and b variable.
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Figure 25: The origin of DTI contrast. (A) Contrast and signal levels in the diffusion-weighted
image of a human brain (left) reflect water diffusion behavior (random walk) (right). Diffusion
behavior is modulated by tissue structure at  the cellular level: For instance, diffusion can be
restricted within cells, water may escape when cell membranes are permeable and might then
experience a tortuous pathway in the extracellular space (hindrance). (B) In the presence of a
magnetic field gradient, magnetized water molecule hydrogen atoms are dephased. The amount
of dephasing  is  directly  related  to  the  diffusion distance  covered by water  molecules  during
measurement. The overall effect of this dephasing is an interference, which reduces MRI signal
amplitudes.  In  areas  with  fast  water  diffusion  (e.g.  within  ventricules),  the  signal  is  deeply
reduced, while in areas of slow water diffusion (e.g. white matter bundles), the signal is only
slightly  reduced.  This  differential  effect  results  in  a  contrast  in  the  diffusion-weighted  MRI
images, which is not visible in standard MRI images. Adapted from (Le Bihan, 2014)
The measured  ADC value  can  vary  because  the  diffusion may not  be  uniform in  all
orientations. To overcome this issue different images with fixed b but different gradient
orientations can be acquired. In Figure 26a is illustrated an ideal phantom that consists of
two parts. An upper part that contain ordered structures, shown as arrows, that represent a
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bundle of axons or well-organized neurons with coherent tissue orientations. A lower part
that contains random structures without coherent orientations. In the right panel of Figure
26a is  shown what happen when ADC is measured along three different  orientations,
these measurements in the upper part of the phantom show orientation dependence (i.e.
anisotropic diffusion). Thus the image intensity, representing ADC values measured in the
orange  box,  change  from high  to  low when  the  measuring  orientation  changes  from
horizontal to vertical. When ADC is measured in the lower part the image intensity does
not change due to the random orientation of structures. 
A mathematical  model  (Basser  et  al.,  1994a,  1994b) can  be  applied  to  estimate  the
components of the effective diffusion tensor that can be visualized as an ellipsoid. The
length of this ellipsoid,  Figure 26b, is proportional to the eigenvalues of the diffusion
tensor (λ1, λ2, λ3). The size, shape, and orientation of each ellipsoid can be described by
combinations of these components corresponding to the diffusion tensor.
Where: 
• Mean Diffusivity: MD=
(λ1+λ2+λ3)
3
 [7]
• Axial Diffusivity (often indicated as λǁ): AD=λ1 [8]
• Radial Diffusivity (often indicated as λ┴): RD=
(λ1+λ2)
2
 [9]
• Fractional Anisotropy: FA=√(λ1−λ2)2+(λ1−λ3)2+(λ2−λ3)22(λ12+λ22+λ32)  [10]
• Relative Anisotropy: RA=√(λ1−λ2)2+(λ1−λ3)2+(λ2−λ3)2(λ1+λ2+λ3)2  [11]
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In the anisotropy map,  (Figure 26b), the upper part of the phantom has higher diffusion
anisotropy than the lower part. Consequently, when the diffusion anisotropy is high, the
long axes of the diffusion tensor often coincide with the underlying structural orientation
and can be visualized using a direction-encoded color map (DEC) where regions with
structural orientation running horizontally are red and those running vertically are green.
Transition areas become yellow, a mixture of red and green. 
Figure  26: From diffusion anisotropy to diffusion tensor. (a) An ideal phantom composed by
ordered (upper part) and random (lower part) structures. The image intensity is high when the
structures have the same orientation as the diffusion gradient applied (represented by the hand).
(b) Diffusion tensors visualized as ellipsoids and rendered as anisotropy and orientation-encoded
color maps. (J. Zhang et al., 2012)
The tensor-derived scalar indices are used to generate grayscale images for visualization
and quantification. In Figure 27 are represented the DTI contrasts of a mouse brain. In the
mean  diffusivity  image  the  CSF  appears  bright  while  the  mouse  brain  parenchyma
appears  rather  homogeneous.  The axial  diffusivity  and radial  diffusivity  images  show
more contrasts between GM and WM structures than the mean diffusivity image. The
corpus  callosum (CC)  has  higher  axial  diffusivity  values  and lower  radial  diffusivity
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values than the neighboring cortical  regions.  In the FA and RA images,  major  white-
matter structures, such as the CC, can be distinguished from GM structures by their high
anisotropy  values.  In  the  DEC  image,  the  CC  appears  red  because  most  fibers  are
arranged along the left–right orientation. 
Figure 27: DTI contrasts in the mouse brain. The CSF in the ventricle is indicated by the white
arrow. The CC is indicated by yellow arrows. The unit for mean, axial, and radial diffusivity is
μm 2/ms. FA and RA are unitless. In the DEC image, major white-matter tracts characterized by
high anisotropy are shown with color-coded orientations. The color scheme is: red, left–right;
green, rostral–caudal; and blue, superior–inferior. (J. Zhang et al., 2012)
Different  models  have  been proposed to  explain  how cell  infiltration  in  white-matter
regions might influence the diffusion anisotropy and diffusivity measurements (Figure
28). The presence of axon and myelin injury during early stages will lead to decreases in
axial diffusivity and increases in radial diffusivity  (Sun et al., 2008).  When axon and
myelin debrils are removed both axial and radial diffusivity increase (Mac Donald et al.,
2007). The presence of inflammation infiltrating cells will contribute to decrease of axial
diffusivity but an increase of radial diffusivity.
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Figure  28:  Schematic diagrams illustrating how complex neuropathology can affect  DTI results.  (a)
Normal myelinated axons and the corresponding diffusion tensor and axial and radial diffusivity (λ || and
λ⊥ , respectively). The diffusion tensor is represented by the ellipsoid here, and is shown in subsequent
plots  as  a  grey  ellipsoid  with  dashed  lines.  (b,c)  Axon  and  myelin  injury  with  and  without  cell
infiltration. (d,e) Axon and myelin injury with axonal loss, with and without cell infiltration. (J. Zhang et
al., 2012)
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1.2.6 – Functional Magnetic Resonance Imaging
The fMRI technique takes advantage of the blood oxygen level–dependent (BOLD) signal
change that occurs when a brain region is more active (Ogawa et al., 1990; Ogawa and
Lee, 1990) Deoxyhemoglobin is, in fact, paramagnetic but when it’s bound to oxygen,
oxyhemoglobin, becomes diamagnetic (Pauling and Coryell, 1936). When red blood cells,
containing  lower  levels  of  deoxyhemoglobin,  are  recruited  by  neural  activation,
differences in magnetic susceptibility between the blood and the surrounding tissue can
induce small magnetic field distortions that may influence the relaxation process of water
protons and thus a local signal change (Figure 29).
To detect spontaneous activity fluctuation in different brain regions, long time series of
MRI images are acquired. The functional networks can be identified by correlating the
BOLD time course from a local  region of interest  with the time course of all  voxels
within the entire brain region (Figure 30). 
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Figure  29: Origin of the fMRI contrast. On the left a hypothetical distribution of vascular and neural
elements in a voxel of the MRI image (indicated by red lines). The drawing shows vessels surrounded
by some of the typical neuronal types. On the right, a schematic illustration of the origins of the BOLD
effect in fMRI. While arterial blood is similar in its magnetic properties to tissue, deoxygenated blood is
paramagnetic and so induces inhomogeneities within the magnetic field in tissue. These cause the MRI
signal to decay faster. Signals from activated regions of cortex increase as the tissue becomes more
magnetically uniform. Adapted from (Gore, 2003; Logothetis, 2008)
Thus, a functional network may be broadly defined as a set  of brain regions that are
consistently  synchronous.  These  networks  are  usually  represented  as  color  coded
activation maps describing the correlation strength between regions (Figure 31). 
Figure 31: Resting-state networks in the mouse brain. Subdivided into isocortical, striatal, thalamic, and
hippocampal networks. Each network is represented in the three-dimensional view and can be identified
by the color of the square box. The strength of the correlation is represented by the Z score. (Grandjean et
al., 2017)
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Figure 30: Main steps involved into fMRI data analysis. First identifying a number of network nodes (or
functionally  distinct  brain  regions)  and  then  estimating  the  functional  connections  (network  edges)
between these nodes. (Smith et al., 2013)
Among all of the networks that can be identified, the Default Mode Network (DMN) is a
group of brain regions that are active in the absence of a task in rodents, primates and
humans  (Figure  32).  It  includes  the  posterior  cingulate  cortex/precuneus,  medial
prefrontal  cortex,  inferior  parietal  lobules,  lateral  temporal  cortices,  and hippocampus
(Buckner et al., 2008; Raichle et al., 2001). It has been advanced the hypothesis that the
DMN activity is involved in the memory consolidation process (Fox and Raichle, 2007).
Figure 32: Comparison of the DMN in rat, monkey, and human. For rat DMN (Left), significant clusters
include: 1, orbital cortex; 2, prelimbic cortex (PrL); 3, cingulate cortex (CG1, CG2); 4, auditory/temporal
association  cortex  (Au1,  AuD,  AuV,  TeA);  5,  posterior  parietal  cortex;  6,  retrosplenial  cortex,  which
corresponds to posterior cingulate cortex in humans; 7, hippocampus (CA1). (Center) Connectivity maps
in the axial plane. Note the strong connectivity between prefrontal and posterior cingulate cortices, which
can best be visualized in the sagittal plane (Bottom, medial-lateral: +0.4 mm). FrA, frontal association
cortex; MO, medial orbital cortex; R, right; RSG/RSD, granular/dysgranular retrosplenial cortex. Color
bar indicates  t scores (n = 16, thresholded at  t > 5.6, corrected  P < 0.05). Numbers below images are
approximate coordinates relative to bregma. For  human DMN (Right),  significant clusters include: 1,
orbital frontal cortex; 2/3, medial prefrontal cortex/anterior cingulate cortex; 4, lateral temporal cortex; 5,
inferior parietal lobe; 6, posterior cingulate/retrosplenial cortex; 7, hippocampus/parahippocampal cortex
(n = 39, thresholded at  z > 2.1,  corrected  P < 0.05).  For  monkey DMN (Center): 2/3, dorsal  medial
prefrontal cortex; 4/5, lateral temporoparietal cortex (including area 7a and superior temporal gyrus); 6,
posterior cingulate/precuneus cortex; 7, posterior parahippocampal cortex. (Lu et al., 2012)
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1.3 – Aim of the Thesis
Thank to  its  versatility,  MRI has  become a  fundamental  tool,  providing a  variety  of
techniques used to study the morphological and physiological changes associated with the
progression of AD. The development of small-bore MRI scanners allowed the translation
of the same procedures to the study of AD transgenic models enabling the creation of a
link  between  macroscopic  imaging  alterations  and  molecular/cellular  aspect  of  the
pathology. Therefore, the principal aim of the present work is to provide a multi-modal
panel of MRI techniques, in order to characterize the metabolic, structural and functional
phenotype of AD mouse models. 
Since  glucose  is  the  central  nervous  system’s  only  energy  source,  imaging
techniques capable of detecting pathological alterations of brain metabolism are useful for
assessing  the  evaluation  efficacy  of  therapies  in  pre-clinical  and  clinical  stages  of
neurodegenerative  diseases.  The  development  of  an  MRI  method  which  can  detect
pathological  alterations  in  the  brain  metabolism  of  AD  transgenic  models  will  be
presented. In particular, since the injection of D-glucose has been proposed as an MRI
contrast agent to ease the identification of tumors, the measure of the 2DG brain uptake
by CEST MRI will  be  tested  as  a  possible  alternative  to  PET imaging in  preclinical
studies of neurodegenerative diseases. Although [18F]FDG-PET is  a technique widely
adopted  in  the  clinical  studies,  it  suffers  certain  drawbacks  such  as  the  low  spatial
resolution.  Moreover,  the  need  of  special  infrastructure  to  synthesize,  distribute  and
dispose  of  radioactive  tracers  makes  it  expensive  and  limits  repeated  longitudinal
measurements.
With the objective to carry out preclinical MRI studies characterized by a high
translational impact, the analysis pipelines developed for investigating alterations in brain
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morphology  and  in  the  brain  structural  connectivity,  were  adapted  to  resemble  the
procedures used in clinical studies. The quantity of information that can be obtained with
these approaches is higher compared to the manual analysis procedures. Moreover, these
approaches are independent of the operator resulting in more powerful and reproducible
results, reducing the time needed for the manual delineation of ROIs and leading to the
reduction of the number of animals necessary for the research.
Since  the  functional  alterations  are  one  of  the  earliest  event  occurring  several
years before the onset of the AD (Clark et al., 2012), the rsfMRI analysis pipeline, that
was recently introduced within the frame of  the Human Connectome Project,  will  be
adapted to rodent studies. The efficacy of this approach has been recently demonstrated in
the  analysis  of  mouse  rsfMRI  data  (Zerbi  et  al.,  2015).  However,  since  various
experimental factors make the application of the rsfMRI technique easier in rats than in
mice, a preliminary rsfMRI experiment will be carried out in rats. The final objective will
be  to  optimize  the  analysis  pipeline  and  translate  it  to  the  study  of  brain  functional
alterations of AD transgenic models.
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Chapter 2: Material and Methods.
All  the  procedures  involving  animals  and  their  care  were  conducted  according  to
European Union (EEC Council Directive 86/609, OJ L 358,1; December 12, 1987) and
Italian  (D.L.  n.116,  G.U.,  Suppl.  40,  February  18,  1992)  laws  and  policies,  and  in
accordance with the United States Department of Agriculture Animal Welfare Act and the
National Institutes of Health (Bethesda, MA, USA) policy on Humane Care and Use of
Laboratory  Animals.  They were  reviewed and approved by the  Mario  Negri  Institute
Animal Care and Use Committee that includes ad hoc members for ethical issues, and the
Italian Ministry of Health (project number 926/2016-PR). 
2.1 – Experimental plan
Experiments were carried out with the following timeline:
1) Preliminary CEST studies were carried out  in-vitro and in-vivo to  optimize the
experimental  procedures  that  would  have  been  adopted  in  the  following
experiments. 
2) A study to test the tolerance of two different 2DG doses (0.5g/kg and 1g/kg) in
wild-type (WT) C57BL/6N mice. 
3) A study was carried out  on APP23 mice over-expressing the human full-length
AβPP (AβPP751) harboring the “Swedish” double mutation (K670N/M671L) breed
on C57BL/6N genetic background  (Balducci et  al.,  2010; Balducci and Forloni,
2011;  Sturchler-Pierrat  et  al.,  1997).  The aim of  this  experiment  was  to  assess
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whether differences in the brain uptake of 2DG between 20 months aged APP23
transgenic (N =7) and age-matched WT mice (N=7) are present. 
4) A multi-parametric and longitudinal study (at 6, 12 and 20 months of age) on a
group of APP23 mice (N=9) and WT littermates (N=9) was assessed. Each time-
point was divided into two MRI sessions. A first one with anatomical, DTI and T2
maps and after one week the 2DG-CEST. A further time-point at 24 months of age
was done without the acquisition of the 2DG-CEST since elderly mice could have
not tolerated well the injection of 2DG. Aim of this experiment was to assess the
reproducibility of results previously obtained at 20 months of age with 2DG-CEST
but also to investigate if a metabolic impairment can be observed in earlier stage of
the pathology and whether concomitant structural alterations are present.
5) A rsfMRI study was carried out on thirty five male winstar rats (weight ~ 300g) to
optimize the post-processing analysis protocol. A baseline acquisition was firstly
reordered,  rats  were  than  separated  into  four  groups  receiving  different
pharmacological  challenges:  Saline (N=8, iv);  Nicotine (0.05 mg/kg,  iv,  N=10);
Nicotine  (0.1  mg/kg,  iv,  N=8);  Mecamylamine  (subcutaneous  3  mg/kg,  N=9)
followed by Nicotine (0.1 mg/kg, iv) 30 minute later.
Animals  were housed in  standard conditions  on a  12-hour  dark/light  cycle,  with free
access  to  food  and  water  before  imaging.  Respiration  was  monitored  during  the
experiment and body temperature maintained at approximately 37°C by a warm water
circulating heating cradle. Mice were anesthetized with isoflurane (4%) in oxygen and
anesthesia maintained with isofluorane (2%). Anesthesia protocol was slightly changed
for  CEST experiments  to  detect  alterations  in  the  uptake  of  2DG.  Mice  were  fasted
overnight, with free access to water before imaging and anesthesia was maintained with
isoflurane (1.5%) in oxygen. After the induction of the anesthesia, the tail vein of these
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mice was cannulated with a catheter connected to a solution of 2DG. Rats used in rsfMRI
experiments anesthetized with isoflurane (4%) in a mixture of O2 (30%) and N2O (70%)
that was slowly discontinued and maintained with an intravenous [iv] infusion in the tail
of a medetomidine solution (0.14 mg/kg/h at 1 ml/h). 
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2.2 – Acquisition parameters
Experiments were done on a 7T Bruker Biospin 70/30 Avance III system, equipped with a
12 cm diameter gradient coil (400 mT/m) and running ParaVision 5.1. 
Mice experiments were carried out with a set of two actively decoupled radio frequency
coils: A 7.2 cm diameter volume coil as the transmitter and a quadrature single channel
surface coil as the receiver. While rsfMRI experiments were done using a 7.2 cm diameter
volume resonator coil as transmitter in combination with a four-channel receive-only coil
array for the rat brain as a receiver. 
2.2.1 – In-vitro CEST
Experimental parameters, such as the saturation power and time, were chosen on the base
of a previously published paper (Nasrallah et al., 2013).  CEST Z-spectra were measured
using  a  rapid  acquisition  with  relaxation  enhancement  (RARE)  sequence  (TR/TE
5000/4.3 ms, RARE factor 24, single slice thickness 2 mm, matrix size 45×45, field of
view 16×16 mm2, resulting in an in-plane resolution of 0.35×0.35 mm2) preceded by a
continuous wave saturation pulse (B1 =1.5 μT, tsat=4 s) over 58 frequency steps (300 ±20
±5 ±4.66 ±4.33 ±4 ±3.83 ±3.67 ±3.5 ±3.33 ±3.17 ±3 ±2.83 ±2.67 ±2.5 ±2.33 ±2.17 ±2
±1.83 ±1.67 ±1.5 ±1.33 ±1.167 ±1 ±0.83 ±0.67 ±0.5 ±0.33 ±0.167 0 ppm) resulting in a
total scan time per Z-spectrum of around 8 min. 
To assess the goodness of the chosen parameters, preliminary in-vitro experiment were
carried out on a phantom that consisted in six glass micro-tubes (ϕ = 2mm) filled with a
solution of 2DG  (Santa Cruz Biotecnology) at different concentrations (0, 7, 15, 30, 60,
120 mM and pH 7) and positioned in a 15ml falcon that was filled with 1 × phosphate-
buffered saline (PBS).
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A Matlab script was used to fit the in-vitro Z-spectra with a spline curve and B0 shift
automatically  compensated  evaluating  the  minimum  of  the  acquired  spectra.  Results
obtained, Figure 33, show that we were able to detect efficiently the asymmetry at all the
2DG concentrations tested, included the lower ones (7 and 15 mM) selected in the range
of the glucose brain concentrations (2-20mM) (Silver and Erecińska, 1994).
Figure 33: In-vitro results. a) Unsaturated slice and color coded map representing
the asymmetry at 1.2 p.p.m. c) Z-Spectra and d) Asymmetry curves at different
2DG concentrations. e) plot of the asymmetry at 1.2 p.p.m as a function of the
concentrations.
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2.2.2 – In-vivo CEST
Before CEST measurements, a B0 field map was acquired and 1st and 2nd order shims
adjusted using the MAPSHIM routine, over a voxel (5×7×7.5 mm3) set to cover the brain,
excluding the olfactory bulb and cerebellum.  CEST Z-spectra were measured using the
same pulse  sequence used in  in  vitro tests  and positioned in  the  dorsal  hippocampus
region (as shown in Figure 34). 
Figure 34: CEST slice positioning
Since B0 inhomogeneities could lead to errors in the evaluation of the CEST effect, the
simultaneous mapping of the B0 and B1 inhomogeneities was assessed using the WASABI
(Schuenke et  al.,  2016)   obtained with a continuous wave saturation pulse (B1=3,7μT,
tsat=5ms, 43 frequency offsets between ±1.5 ppm). 
As  shown  in  Figure  35,  each  experiment comprised  the  simultaneous  B0 and  B1
inhomogeneities  mapping  and  two  different  paradigms  followed  by  one  last  “high-
resolution”  unsaturated  reference  image  that  was  acquired  with  a  RARE  sequence
(TR/TE=5000/4.3 ms, RARE factor 16, slice thickness 2 mm, matrix size 90×90, field of
view 16×16 mm2 resulting in an in-plane resolution of 0.18×0.18 mm2). 
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Figure 35: Timing of the experiment
2.2.3 – Anatomical images
An in-house high resolution reference template was created by acquiring ten anatomical
T2-weighted  images  on  wild-type  mice.  A  3D  rapid  acquisition  with  relaxation
enhancement (RARE) was used with a voxel size of 83 × 83 × 83 µm3 (matrix size 360 ×
164 × 128 and FOV of 3 × 1,36 × 1,06 cm); TR= 2500 ms, effective echo time TEeff = 50
ms, and RARE factor of 16, for 1 average and acquisition time of 54 min.
During the longitudinal study, anatomical images of APP23 and littermates WT mice were
acquired with different acquisition parameters: voxel size of 100 × 100 × 100 µm3 (matrix
size 300 × 100 × 120 and FOV = 3  × 1 × 1.2 cm), TR = 2500 ms, TEeff = 50 ms, and
RARE factor of 16, for 1 average and acquisition time of 30 min. Reducing  the scanning
time it is possible to acquire other image modalities without protracting anesthesia for a
long time. 
2.2.4 – DTI images
Coronal  DTI  echo-planar  imaging  (EPI)  sequences  acquired  with  an  in-plane  image
resolution of 117 × 156 μm2 (FOV 1.5 × 1.5 cm2, acquisition matrix 128 × 96, 18 slices
with thickness of 0.5 mm); TR/TE=4500/32 ms. Four averages were used to boost the
signal-to-noise ratio. Diffusion, encoding b factors of 800 mm2/s was applied along 19
isotropic directions, acquistion time 24 min. 1st and 2nd order shims were adjusted using
the MAPSHIM routine, over a voxel (5 × 7 × 8 mm3) set to cover the brain before DTI
measurements.  A 2D coronal  anatomical  reference image was acquired with a  RARE
sequence with an in-plane resolution of 76 × 76 μm2 (TR/TEeff = 4000/52, RF = 8, FOV =
1.5 × 1.5 cm2, acquisition matrix 196 × 196, 18 slices with thickness of 0.5 mm, for a total
scan time of 6 min). 
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2.2.5 – Multi slice multi echo images (MSME)
The T2 values of the tissues was estimated acquiring a multi slice multi echo (MSME)
sequence with TR=3500ms and ten different TE (11, 22, 33, 44, 55, 66, 77, 88, 99, 110
ms) with an in-plane image resolution of 76 × 76 μm2 (FOV 1. 5 × 1.5 cm, acquisition
matrix 196 × 196, slice thickness 1 mm), acquisition time 8 min. 
2.2.6 – rsfMRI images
After the acquisition of a tripilot scan, to correctly position the brain in center of the
scanner,  an anatomical  reference  scan  was  acquired  using  a  T2-weighted  Rapid
Acquisition  with  Relaxation  Enhancement (RARE)  sequence  with  the  following
parameters: field of view (FOV) = 36 × 25 × 24 mm3, matrix dimension (MD) = 240 ×
124 × 64, repetition time (TR) = 2500 ms, effective echo time (TEeff) = 60 ms, RARE
factor = 20, number of averages (NA) = 1. 
B0 field homogeneity correction were made with the Bruker Mapshim routine over  a
region of interest that covers the entire brain volume. A fieldmap acqusition was acquired
twice, before and after the B0 correction.
The fMRI time series were acquired using a single-segment gradient-echo planar imaging
(EPI) sequence with: TR/TE=2000/20ms; MD= 92 × 92; FOV=35 × 35mm2; 27 slices
with thickness of 0.5 mm and slice gap of 0.2 mm; 300 volumes. 
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Chapter 3 – Results
This chapter include three main sections that illustrate the results obtained respectively in
the study of brain metabolism and structural alterations of the transgenic mouse brain and
the development of the rsfMRI method.  The description of the analysis  procedures is
included in this chapter because their development is itself a result obtained in the frame
of this project. 
3.1 – Study of the mouse brain metabolism with 2DG-CEST
Aim  of  the  experiments  described  within  this  section  was  to  develop  a  novel  MRI
technique, alternative to the [18F]FDG-PET, able to detect pathological alterations in the
brain glucose metabolism of Alzheimer's disease transgenic mice.
3.1.1 – CEST analysis workflow 
All the analysis have been done with custom MATLAB scripts. All the steps needed by
the developed analysis  pipeline are  shown in  Figure 36 and consist  of three different
steps:
• B1 and  B0 mapping.  Needed  because  CEST  effect  is  susceptible  to
inhomogeneities of the static magnetic field and of the RF saturation pulse.
• Paradigm 1:  To  analyze  the  full  Z-spectra  acquired  before  and after  the  2DG
injection.
• Paradigm 2: To analyze the data acquired dynamically during the 2DG injection.
68
Figure 36: Flowchart describing the CEST data processing procedures. Diamonds shape indicate
the processing steps done with the developed software while square boxes indicate processed
images. 
B1 and B0 mapping. CEST effect is susceptible to the B0 inhomogeneity of the static
magnetic field; because of the presence of the so called “spillover effect” the measured Z-
specturm is no longer symmetric resulting into an erroneous evaluation of the asymmetry
curve  Figure 37.  Furthermore,  the B1 inhomogeneity of the RF pulse may also cause
spatial variation in the saturation efficiency affecting the CEST quantification (G. Liu et
al., 2013). 
The most commonly adopted method to correct the B0 inhomogeneity is called “water
saturation shift referencing (WASSR)” (M. Kim et al., 2009). Through a weak intensity
preparation block (one rectangular pulse with pulse duration tp = 500 ms and nominal RF
amplitude  B1=0.1µT and 31 frequency  offsets),  followed by a  spoiler  gradient  and a
conventional  MRI  readout,  it  allows  the  direct  measurement  of  the  absolute  water
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frequency in each voxel and enables a proper centering of Z-spectra on a voxel-by-voxel
basis  (Figure  37).  However,  since  WASSR  method  does  enable  to  map  the  B1
inhomogeneity mapping, a separate sequence should be adopted extending the acquisition
time.
Figure  37: Simulated Z-spectra (dashed lines) and MTRasym plots (solid lines) for an
amide proton (a,c,e) and a glycogen OH proton (b,d,f). The large intensity drop around 0
ppm is due to direct water saturation, with the water frequency assigned to 0 ppm. a: An
amide proton at 3.5 ppm shows a clear CEST effect in both the Z-spectrum and MTRasym
plot. b: A glycogen OH proton at 1 ppm shows a relatively clear but small CEST effect in
the MTRasym plot, but the CEST effect is not clearly visible in the Z-spectrum because
the  OH  protons  resonate  close  to  the  water  frequency.  When  the  direct  saturation
lineshape broadens (c and d), the CEST effects of the amide and OH protons can be still
observed  in  the  MTRasym plot  as  long  as  the  saturation  curve  is  properly  centered.
However, a shift as small as 0.1 ppm in the Z-spectra can cause relatively large changes in
MTRasym, affecting the CEST quantification of the amide proton (e) and obviating the
CEST effect of the OH proton (f). (M. Kim et al., 2009)
The  WASABI  method  adopted  allows  the  simultaneous  mapping  of  the  B0 and  B1
inhomogeneities. It consists of a short preparation block (one rectangular pulse with pulse
duration tp = 5 ms and nominal RF amplitude B1 = 3.7 µT), followed by a spoiler gradient
and a conventional MRI readout. Sampling of several frequency offsets around the water
resonance reveals the sinc‐shaped saturation spectrum of the pulse (Figure 38), from
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which the absolute water frequency δω and the B1 amplitude can be derived. The shape of
the saturation spectrum can be described mathematically by the following equation:
Z (Δω)=|c−d⋅sin 2( tan−1( γ⋅B1Δ ω−δω ))⋅sin 2(√(γ⋅B1)2+(Δω−δω)2+
t p
2 )| [12]
Where the tp is the pulse duration and the γ is giromagnetic ratio are constant and c, d, B1,
and δω the free parameters estimated. 
Figure 38: Simulated WASABI Z-spectra. (a) Shows the effect of the RF amplitude (B1) on the shape of the
signal. (b) The water frequency shifts δω. (Schuenke et al., 2017b)
A high correlation between the B0 map obtained with the WASABI method with the ones
obtained with the WASSR have been measured, as shown in Figure 39.
Figure  39: Comparison between B0 map obtained with the WASABI and the WASSR approaches.  a)
linear correlation between values calculated with the two methods in each voxel. b and c) Color-coded
maps representing the shift from the absolute water frequency (δω) calculated in the mouse brain region
with the two methods. 
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An example of a measured wasabi-spectrum is shown in Figure 40. A relative B1 map can
be obtained by normalizing the measured B1 map by the setting value (3.7µT) equal to the
selected RF amplitude.
Figure 40: Fit results of the WASABI technique. In (a) is shown a example of an acquired spectra
and the fit obtained. In  (b) a relative B1 map obtained within the mouse brain region. The color-
coded map shows that regions with rB1 close to 1 are those where RF amplitude is closer to the
setting value (3.7µT).
Paradigm 1: Z-spectrum asymmetry changes.  As shown in Figure 35, three baseline
Z-spectra were acquired before the injection of the bolus and six more Z-spectra acquired
after. Each one was evaluated voxel-wise within a mask brain region that was manually
drawn  using  ITK-SNAP software  (Yushkevich  et  al.,  2006)  using  a  multi-lorentzian
fitting approach  (Jones et al., 2013; Wang et al., 2016). Each CEST Z-spectrum signal,
expressed as  a  function of the frequency offset  (Δω),  was modeled as a  sum of  five
inverted Lorentzian curves with amplitude (Ai) and full width half maximum (Li). 
Z ( Δω )=1−∑
1
5
A i(1+( Δω−δωi0.5 ⋅Li )
2
)
−1
+MT [13]
This represents the effect of the saturation on the signal intensity directly on the free
water molecules and from the exchanging amine (-NH2), amide (-NH), hydroxyl (-OH)
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and the signal of aliphatic protons (relayed nuclear Overhauser effect rNOE). While the
semi-solid  magnetization  transfer  contribution  was  considered  just  as  an  additional
parameter since the saturation power is weak and calculated as:
MT=
[S0−S5 ppm ]
S0
[14]
where S0 is the signal with saturation pulse at 300 ppm.
To ensure a reliable fit careful correction of the B0 inhomogenities the fit function of the
Z-spectrum signal was evaluated with a slightly different procedure from the previously
published (Desmond et al., 2014; Wang et al., 2016; Windschuh et al., 2015; Zaiss et al.,
2011; Zhou et al., 2017) by splitting it into two subsequent steps as shown in Figure 41. 
Figure 41: Fitting procedure. The left panel shows the location of the different compounds. Analysis firstly
fitted the contribution of water and NOE (part A) and in a second step the other compounds contributions
(part B).
To avoid over-fitting errors, direct water saturation (DWS) and the contribution of NOE
protons were firstly evaluated as the sum of two Lorentzian curves over the non-hydroxyl
containing region using a subset of frequency offsets (Miller et al., 2015) between -6 ppm
and 0.5 ppm The water shift (δω) starting point was set using the previously calculated B0
map and signal drifts were corrected using the minimum of the water Lorentzian curve.
Then the residue signal was fitted by the sum of the three remaining proton groups. This
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approach has the advantage of allowing a better correction of the 0 ppm offset of the Z-
spectrum without any potential bias due to effects present elsewhere in the spectrum, this
is then incorporated into the model as compensation in the second step. We have observed
a signal drift that results in a shifting of the Z-spectrum during the experiment that can
cover 90 minutes, hence the need for a direct correction as part of the fitting. Although the
traditional evaluation of the six-pool approach in a single step is able to produce good
looking fit  and low residuals it could lead to errors in the evaluation of the hydroxyl
protons when combined with unconstrained fitting of other parameters. In Figure 42 and
43 the fit obtained within the same voxel, 20 minutes before the 2DG injection and 60
minutes after and analyzed with the two approaches, are shown. In  Figure 42 it can be
seen that, with the single step six-pool approach, good results can be obtained just with
the first Z-spectra when the B0 map was calculated using the WASABI sequence right
before the Z-spectra acquisition. Although the B0 shift produced by the signal drift is not
very  large,  we  observe  that  it  can  influence  the  quality  of  the  single-step  six-pool
approach that gives a wrong estimation, leading to a wrong asymmetry curve that presents
negative values close to the zero point. This could be due to an over-fitting error; with a
high number of unconstrained variables in the fitting procedure less robust results were
obtained. Hence our approach was to initially shift the signal using the B0 map obtained
with the WASABI sequence, then we fit the right part of the Z-spectra as the sum of two
lorentzian contribution (Water and NOE) between 0.5ppm and -6ppm. After fixing the
parameters belonging to water and NOE we evaluate other pools. This approach avoids
the  hydroxyl  contribution  being  erroneously  assigned  to  the  water  pool.  Moreover,
considering  the  MT contribution  constant  we further  reduce  the  number  of  variables
involved  into  the  fitting  procedure  obtaining  more  robust  results  Figure  43.  Both
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approaches published starting points and boundaries of fit  parameters have been used
(Windschuh et al., 2015).
Figure 42: Six pool fitting procedure within the same voxel (a) 20 minutes before and (b) 54 minutes after
the 2DG injection. With the black arrow is show that, although a good looking fit is obtained, an error in the
asymmetry curve is obtained due to the erroneously compensated B0 signal drift.
Figure  43: Five pool fitting procedure separated into two different steps. Within the same voxel (a) 20
minutes before and (b) 54 minutes after the 2DG injection.
To assess the accumulation in brain cells of 2DG, and therefore of 2DG6P, the differences
between the three baseline and the post-injection Z-spectra were measured as the change
of the asymmetry of the fitted signal in each voxel of the brain mask. 
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The asymmetry curve is normally obtained as:
MTRasym=
Sref −S lab
S0
[15]
where Sref and Slab are the measured signal intensity and the label intensity of the acquired
Z-spectrum and S0 is the unsaturated signal intensity.  However, since a fit curve has been
computed, the asymmetry can be expressed as a Lorentzian Difference (LD) (Jones et al.,
2013):                                         LD=Zref−Z lab [16]
Where Zref and Zlab are  the corresponding images  with intensities  given by the fit.  In
addition a linear correction for B1 was applied by multiplying the asymmetry curve by the
previously relative B1 calculated. This simplified B1 correction was applied because we
found small B1 differences.
Figure 44: Asymmetry enhancement. Mean asymmetry fitted curves over the cortex region of a single WT
mouse before and after 2DG injection. Highlighted by the square is the area where the cest enhancement
has been evaluated.
The glucose CEST enhancement (GCE) was then expressed as the change of the area
under the lotentzian difference curve (AUCLD) between 2.3 and 1 ppm that corresponds to
the hydroxyl group resonating region (Figure 44) and described by:
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GCE(t )=[ AUC LD (t)−AUCLD (Baseline)AUC LD(Baseline) ] [17]   
To enable an automated regional of interest analysis, a custom template was created using
the buildtemplateparallel.sh script, provided by ANTs  (Avants et al.,  2010, 2011), that
perform the averaging of all the “high-resolution” reference slices acquired at the end of
each experiment. The unsaturated images of each Z-spectra were then co-registered with
an  affine  transformation  and  resampled  to  this  high-resolution  template  The
transformations obtained were then applied to the images describing the GCE and the
mean was calculated over selected regions of interest (ROI) traced over the template in
the cortex, hippocampus, thalamus and ventricles.
Paradigm 2: Continuous single offset acquisition.  In order to reduce the sampling time
and measure changes of the blood-brain volume dynamically, the direct measurement of
the signal change during the 2DG injection (Dynamic-CEST)  (Xu et al., 2015a, 2015b)
was achieved by repeating the saturation (tsat=4 s, B1 =1.5 μT)  in the region of interest of
the  hydroxyl  protons,  1.2  ppm.  The  2DG  bolus  was  injected,  without  stopping  the
acquisition,  after  15  baseline  scans  and  over  a  period  of  90  seconds.  The  dynamic
acquisition covered a total of 90 repetitions and lasted 13.5 minutes.  Since, one image
was obtained every 9 seconds, which intensity depends on the amount of 2DG in the
tissues, the signal change can be established as the difference in the signal intensity from
the baseline calculated averaging the first 15 images. The area under the curve (AUCDyn)
could be related to the amount of blood reaching the brain tissues. It was computed as the
total sum of the differences of the signal from the baseline, starting from the end of the
infusion (110 sec) following:
77
AUC Dyn=∑
n=110
700 [ Sbaseline−S (t n )Sbaseline ] [18]
Images representing the AUCDyn were again co-registered to the template space and wild-
type and transgenic mice compared using student’s t-test and the ROI approach. 
3.1.2 – CEST preliminary in-vivo tests
Results shown within this section were carried out to verify that we were able to detect
the 2DG uptake in the mouse brain with the selected acquisition parameters but also to
find a suitable dose of 2DG to be injected. Obstructing the glucose utilization, high doses
of 2DG could lead to intracellular glucopenia and eventually to death. However, it has
been shown how fairly high doses of 2DG (from 0.25 g/kg up to 2 g/kg) must be injected
to compensate the low sensitivity of the MRI technique (Rivlin et al., 2013, 2014; Rivlin
and Navon, 2016; Jin et al., 2016).  
Two  groups  of  wild-type  mice  (each  with  N=8  and  20  months  of  age)  received
respectively two different dose of 2DG (0.5 g/kg and 1 g/kg). The GCE was measured
averaging the signal changes of the Z-spectrum asymmetry  (Paradigm 1) in the whole
brain slice and in the cortex, hippocampus, thalamus and ventricles regions (Figure 45).
The two-way analysis of variance (ANOVA) followed by the Hochberg correction (R
software, https://cran.r-project.org/) was computed considering all time-points. It did not
shown significant interaction between dose injected and time for all ROIs investigated.
However, a significant effect of time was highlighted when the  GCE was averaged all
over the whole brain mask (F=28.27, p<2×10-16), in the cortex (F=46.64, p<2×10-16) and
in  the  thalamus  (F=16.74,p=3×10-16).  In  the  hippocampus  a  significant  effect  of  time
(F=22.03,p=2×10-16) and a significant effect of the dose injected (F=8.39,p=0.004) was
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shown.  Similarly,  in  ventricles  a  significant  effect  of  time (F=18.33,p=2×10-16)  and a
significant effect of the dose injected (F=4.57,p=0.03) was shown. The significant effect
of time could indicate that the uptake of 2DG is faster after the injection of the higher
dose but at the same time that the concentration of 2DG, and therefore of 2DG6P trapped
in cells, is equal between the two groups at longer times.
Figure  45:  Temporal  GCE. Group mean ± standard errors  (s.e.m.)  are  visualized and injection time is
indicated as zero. ***p <0.001,**p <0.01, *p <0.05. 
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No difference were detected with the paradigm 2; the signal change obtained acquiring
continuously the 1.2 ppm offset present similar trend between the two groups (Figure 46).
The dosage of 1g/kg of 2DG was not well tolerated. Respiration rate struggled to get back
to a normal condition and mice remained unresponsive for many hours after the 2DG
injection.  The  respiration  rate  of  one  of  these  mice  collapsed  during  the  experiment
causing its death and the same happened to other two mice that died in the following
days; the data belonging to these mice were discarded. Mice that received the 0.5g/kg
dose were, on the other hand, able to recover completely within an hour after the end of
the experiment and they were responsive to external stimulation after few minutes. Since
the statistical analysis did not show differences between the two dosage and since mice
did not suffer a dose of 0.5 g/kg we decided to adopt it for the following experiments.
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Figure 46: DynamicCEST measurements. Group mean dynamic curves and AUCDyn obtained by averaging
the signal in the each hippocampus, thalamus and ventricles.
3.1.3 – Detection of the 2DG cerebral uptake in the APP23 mice
A 20-months age group of APP23 mice (N=7) and wild-type littermates were analyzed
with an injected dose of 0.5 g/Kg of 2DG.  The animals were randomized and scanned
over a period of eight days. All mice fully recovered few minutes after the end of the
anesthesia. 
Figure  47: Temporal GCE. Group mean ± standard errors (s.e.m.) are visualized and injection time is
indicated as zero. ***p <0.001,**p <0.01, *p <0.05.
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The two-way ANOVA followed by the Hochberg correction was computed considering all
time-points (Figure 47). A significant decrease of the brain 2DG uptake was detected in
APP23 mice.  When the  GCE was averaged all  over  the whole brain mask, statistical
analysis indicated a significant effect of genotype (F=35, p= 3.9×10-8), a significant effect
of  time  (F=41.44,  p<2.2×10-16)  and  a  significant  interaction  genotype×time  (F=2.8,
p=0.007).  Similarly,  in  the cortex,  the analysis  shows a significant  effect  of genotype
(F=56.46,  p=1.77×10-11),  a  significant  effect  of  time  (F=36.1,  p<2.2×10-16)  and  a
significant interaction genotype×time (F=3.8, p=0.0006). In the hippocampus time and
genotype effects were also significantly different (respectively F=61.5, p<2.2×10-16  and
F=28.67,  p=4.9×10-7)  as  was  the  interaction  genotype×time  (F=2.25,  p=0.03).  In  the
thalamus  and  ventricles  the  single  effects  were  significant  but  not  the  interaction
genotype×time.
All the co-registered images representing the GCE were averaged at different time-points
(Figure 58) enabling a visual comparison of the 2DG accumulation between wild-type
and transgenic mice.
Figure 48:  Graphic representation of the GCE time course. Each frame was obtained averaging all the
images of each timepoint. Baseline shown is the mean of the first three time points.
Since the analysis shown in Figure 47 revealed a significant difference between the two
groups,  we ran  a  voxel-wise student’s  t  test comparing the  GCE images acquired  54
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minutes  after  injection  using  randomise  (Winkler  et  al.,  2014) embedded  in  the  FSL
software  library  (Jenkinson  et  al.,  2012).  The  cortex  area  of  wild-type  mice  shows
significantly  greater  CEST asymmetry  than  the  APP23  transgenic  mice  (Figure  49).
Similarly, a difference was seen in the thalamus area, but does not appear in the ROI
analysis where all the time points were considered.
Figure  49:   Voxel  wise comparison.  T-test  on
the normalized images representing the GCE 54
minutes  after  2DG injection.  In  red the  areas
where WT >APP23 with p < 0.05.
The analysis  of  the  continuous  single  offset  acquisition  by  DynamicCEST,  shown in
Figure 50, revealed a non significant decrease of the AUCDyn in the cortex of APP23 mice.
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Figure  50: DynamicCEST measurements. (a,b) Group mean AUCDyn images normalized to the
template. (c) group mean dynamic curves obtained by averaging the signal in the cortex. (d)
AUC Dyn calculated in the cortex area.
3.1.4 – Longitudinal study of the 2DG cerebral uptake in the APP23 mice
A group of APP23 mice (N=9) and wild-type litter-mates were followed longitudinally at
three different ages (6, 12 and 20 months).  Three APP23 mice and one WT mouse died
around  10  months  of  age  and  two  more  WT mice  died  before  the  last  acquisition.
However, although I cannot exclude that the injection resulted toxic with a longitudinal
2DG treatment,  mice  died  a  certain  amount  of  time  after  the  injection  likely  due  to
external causes probably related to the aging process.
In order to perform a statistical analysis that include the age as a factor, the area under the
GCE curve was computed as the sum of all time points (for each mouse and each ROI):
AUCGCE=∑
t=0
54 min
GCE(t ) [18]
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Figure 51: Temporal AUCGCE. Group mean ± standard errors (s.e.m.) are visualized. ***p <0.001,**p <0.01,
*p <0.05.
Shown in Figure 51, the two-way ANOVA, followed by a post-hoc Hocberg correction,
shows that when the whole brain region is considered a significant interaction between
the genotype and age is present (F= 5.04, p < 0.05) but no significant effect of age and
genotype. As shown in Figure 51, in the cortex region a significant interaction between
the genotype and age is present (F= 3.87, p < 0.05) and a significant effect of genotype (F
=  7.897,  p  =  0.008)  but  not  significant  effect  of  age.  In  the  hippocampal  region  a
significant interaction between the genotype and age (F= 5.39, p < 0.01) and a significant
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effect of age (F = 3.65, p = 0.03) but not significant effect of genotype. In the thalamus
and ventricles no significant differences were detectable.
Figure  52:  Temporal  GCE. Group mean ± standard errors  (s.e.m.)  are  visualized and injection time is
indicated as zero. ***p <0.001,**p <0.01, *p <0.05.
Since no differences could be detected at 6 and 12 months of age, I present the GCE
curves at 20 months of age (Figure 52) showing a similar trend to the one obtained in the
previous experiment (Figure 47). The two-way ANOVA, followed by a post-hoc Hocberg
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correction, shows a significant effect of genotype (F=37.31, p=3.3×10-8) and a significant
effect of time (F=27.10, p<2.2×10-16) but also an interaction between the genotype and
time was present (F=2.81, p<0.008) when the GCE is averaged in the whole brain region.
In the cortex region a significant effect of genotype (F=35.8, p=5.7×10-8) and a significant
effect of time (F=10.17, p=1×10-9) but also an interaction between the genotype and time
was present (F= 2.41, p=0.02). In the hippocampal region a significant effect of genotype
(F=32.1, p=2.2×10-7) and a significant effect of time (F=30.58, p < 2.2×10-16) but also an
interaction  between  the  genotype  and  time  (F=2.26,  p=0.03).  In  the  thalamus  and
ventricles no significant interaction between the genotype and time was detectable
The two-way ANOVA analysis of the area under the curve of the continuous single offset
acquisition (paradigm 2) by DynamicCEST, did not show significant differences in all the
region of interests considered (Figure 53).  
Figure 53: Longitidunal results of the dynamicCEST measurements in the cortex region.
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3.1.5 – Summary (1)
In this section, an MRI method able to detect pathological alteration of the brain glucose
uptake has been developed. The adopted workflow enabled the detection of an increase of
CEST asymmetry after the injection of a 2DG bolus with two different doses (0.5g/kg and
1 g/kg). Since no significant difference in the 2DG-CEST asymmetry was detected, the
lower  doses  was  adopted  in  the  following  in  vivo  studies.  Experiments  in  APP23
transgenic  mice  revealed  a  significantly  decreased  uptake  of  2DG  in  the  cortex  of
transgenic mice when compared to wild-type litter-mates. However, this difference was
seen only in a late stage of the pathology (20 months of age). Similar results have been
described in a longitudinal study showing impaired 2DG uptake in 20 months of age
APP23 when compared to WT mice but no significant differences at 6 and 12 months of
ages. Contrary to the observed metabolism in healthy aged human, that exhibited focal
decreases in brain activity (particularly in the medial network) as a function of normal
aging (Pardo et al., 2007), our longitudinal CEST study revealed an increase of the 2DG
uptake in elderly WT mice. This age-dependent hyper-metabolism has been observed in
different [18F]FDG-PET studies (de Cristóbal et al., 2014; Waldron et al., 2015c; Takkinen
et  al.,  2016;  Matthias  Brendel  et  al.,  2016) and  related  to  an  age-dependent
neuroinflammation (Brendel et al., 2017). 
No  significant  differences  between  APP23  and  WT  mice  were  detectable  with  the
Dymanic-CEST method. Only a slight decrease was seen in the cortex of APP23 mice
that could be driven by a reduction of CBF. This impairment has already been described
in APP23 mice in a late stage of the pathology (Maier et al., 2014). This may indicate that
the dynamic acquisition of CEST images at the saturation frequency of hydroxyl protons
is  not  the  best  method  to  measure  CBF within  the  context  of  the  neurodegenerative
diseases.  Previous  studies  describing  dynamicCEST acquisitions  were  made in  tumor
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lesions where the massive blood volume and glucose consumption compared to healthy
brain makes this technique feasible.
To understand the importance of the results obtained, a visual comparison between the
[18F]FDG-PET and the 2DG-CEST images,  developed within this project,  is shown in
Figure 54. It’s evident that image representing the enhancement of the CEST signal after
the 2DG injection (Figure 54b) is acquired with a better in-plane resolution (equal to 0.35
× 0.35 mm2) than the acquired PET image (Figure 54a). Although both techniques are
characterized by an intrinsic variability, PET is characterized by a modest resolution of
0.8 × 0.8 mm2 (Kuntner  and Stout,  2014).  This  limit  makes  a  reliable  differentiation
between small regions of the mouse brain challenging with images acquired with the PET
technique.
Figure 54: Visual comparison of the two techniques. a) Single WT mouse PET imagerepresenting
18F-FDG uptake 50-60 minutes after injection with a voxel size of 0.78 × 0.78 × 0.8mm3; b)
image representing the GCE of a single mouse 1 hour after the 2DG injection, it has a voxel size
of 0.35 × 0.35 × 2 mm3;  c)  PET image coregistered with computed tomography image and
superimposed  on  a  general  mouse  brain  MRI  template;  d)  GCE  image  coregistered  and
superimposed  on the in-house  template.  SUV = standard  uptake  value;  GCE = glucose  cest
enhancement. (Tolomeo et al., 2018)
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Even if,  due to  the  methodological  differences,  it  is  difficult  to  directly  compare  the
regional distribution observed with the two techniques it is evident that the 2DG-CEST
technique have a great potential since it does not require the use of radioactive tracers and
it could be further optimized by extending the acquisition time or using coils with higher
signal to noise ratio. 
We  cannot  exclude  that  the  different  detected  glucose  distribution  between  the  two
techniques could be due to the rather high doses of 2DG needed by CEST, whereas PET
utilizes non-pharmacological tracer doses. However, the pattern of accumulation observed
with CEST could be compared more in detail with those given by [14C]-2DG or [18F]FDG
autoradiography  (Lundgaard et  al.,  2015; Waldron et  al.,  2015b) or those obtained by
[18F]FDG-PET  in  rats,  whose  larger  brains  allows  the  easier  differentiation  of
accumulation patterns in different brain regions (Zimmer et al., 2014). 
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3.2 – Brain structural alterations of Alzheimer’s disease mouse models
This  section  focuses  on  the  development  and  on  the  application  of  a  panel  of  MRI
techniques  to  characterize  brain  structural  pathological  changes  in  transgenic  mouse
models of neurodegeneration. To improve the translational impact of the reported studies,
these techniques  were directly  adapted from human MRI analysis  procedures  and are
aimed to:
• Investigate alterations in GM morphology. Two different approaches were adopted;
1) A multi-atlas parcellation procedure which is an automated workflow able to
measure the volume different brain regions.  2) A voxel based morphology (VBM)
approach that is able to measure differences in local concentrations of brain tissue,
through a voxel-wise comparison of multiple brain images. 
• To investigate  WM integrity.  By means  of  DTI  measurements  and  an  analysis
workflow  called  “tract  based  spatial  statistic”  (TBSS)  which  is  developed  to
compare automatically WM tracts of multiple images. 
• To investigate alterations in the brain tissue composition. With the measurement of
the T2 relaxation time.
3.2.1 – Brain structural parcellation method
Different  studies  have reported automatic  brain segmentation methods able  to  warp a
single reference brain atlas into the space of an acquired brain enabling the evaluation of
brain regions volume without the need of manual tracing (Ma et al., 2008; Redwine et al.,
2003). However, it has been shown that a multi-atlas approach, that take advantage of the
use of different reference atlases, has a better segmentation accuracy compared to single-
atlas based segmentation (Bai et al., 2012; Ma et al., 2014; Nie and Shen, 2013). 
92
Methods described within this section can be separated into two subsequent steps:
• The creation  of  an  in-house  set  of  mouse  brain  atlases,  to  further  improve the
efficacy the segmentation method.
• The  development  of  the  multi-atlas  segmentation  procedure  and  a  tested  on  a
dataset of images that was manually analyzed in the frame of a previous project.
Brain atlases creation. A set of high-resolution (83  × 83 × 83 µm3) T2-weighted brain
images was acquired using ten wild-type mice to be used as the reference in the following
studies. To obtain the brain anatomical segmentation of each one of these images was
processed following different steps (Figure 56):
• Since the use of the surface coil leads to an artifact that present a signal intensity
that decrease smoothly along the coronal direction across the image, an intensity
non-uniformity  algorithm,  with  the  N4BiasFieldCorrection  tool  (Tustison  et  al.,
2010), was firstly applied (Figure 55). 
Figure 55: Illustrative image showing the result of the bias field correction. (a) The original
subject image which is characterized by higher intensity on the upper part of the brain. (b) The
estimated bias field and (c) resulted corrected image.
• Corrected images were subsequently averaged, with the buildtemplateparrallel.sh
script  (Avants  et  al.,  2011a),  to  create  a  preliminary  template  including all  the
tissues. 
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• This template was normalized to an existing ex-vivo template  (Dorr et al., 2008),
with the antsIntroduction.sh script (Klein et al., 2009), obtaining a brain mask. 
• This  mask  was  back-projected  to  the  original  set  of  images  allowed  the  brain
extraction. 
• The intensity non-uniformity correction was newly computed on the brain extracted
images to improve it’s efficacy (Pagani et al., 2016). 
• Extracted  brains  were newly averaged to  obtain an in-vivo skull  stripped brain
template. To improve segmentation accuracy, this template was newly normalized
to the ex-vivo template and the ex-vivo atlas back-projected to the in-vivo brains.
These in-vivo atlases were manually slightly modified in order to correct mistakes
that are due to the differences between the in-vivo average template and the ex-vivo
reference template, which present a different intensity range and local deformations
due to the perfusion of the brains used to create it.
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Figure  56: Workflow followed to create the in house atlases.  Acquired images are corrected and
averaged to create an in house Template. This is normalized over an ex vivo template and masked.
The template mask is projected to the reference images that are subsequently masked and averaged to
create an in-house skull stripped template. This brain template is again normalized over the ex-vivo
template and reference atlases obtained back-projecting the ex-vivo atlas.
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Multi-atlas segmentation. All the anatomical brain images acquired in the longitudinal
study  were  preprocessed  by  correcting  the  non-uniform  bias  field  and  parcellated
following the steps (Figure 57):
1. Each subject was warped to the full template and the template mask was back-projected
to the subject space obtaining the subject mask and therefore the brain extraction.
2. A multi-atlas segmentation approach, using the antsJointLabelFusion.sh script (Wang et
al., 2013) embedded in the ANTs software (Avants et al., 2014) have been used to warp
the ten brains templates to the subject brain
3. The reference atlases were back-projected to the subject space and fused together to
create the anatomical parcellation. 
Figure  57: Automatic parcellation procedure.  Firstly  the brain extraction is  performed (yellow arrows).
Subsequently  the  normalization  of  the  reference  images  to  the  subject  brain  (red  arrows)  allowed the
projection and the fusion of all the reference atlases to the subject space (blue arrows).
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Accuracy test. A preliminary test  was carried out to segment a dataset of anatomical
brain images that was manually segmented within the frame of a previous project. These
brain images were acquired on a group of aged (24 months) APP/PS2/Tau mice which
have a mutation on the tau gene (P301L) besides APPswe  and PS2(M141I) mutations
(Rhein et al., 2009). Manual segmentation revealed an age-dependent hippocampal and
entorhinal cortex atrophy in APP/PS2/Tau mice when compared with WT (Micotti et al.,
2015). 
A comparison between the volumes obtained manually with the ones obtained with the
automated parcellation procedure showing a high correlation. Notably, both methods were
able to distinguish between WT and APP/PS2/Tau mice (Figure 58) suggesting that the
automated parcellation method here described is able to give reliable results. 
Figure  58: Volumes of different regions obtained with the automatic parcellation method and with the
manual tracing shows high correlation.
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3.2.2 – Longitudinal brain structural parcellation of the APP23 mice
Once established that the automated method is robust, it was applied to the analysis of the
APP23 bran images that were acquired longitudinally within the frame of this project.
Figure 59: Volumes of the brain regions.
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The statistical analysis did not show a significant interaction between age and genetic
background  comparing  the  volumes  of  the  brain  region  obtained  with  the  automatic
parcellation method in the longitudinal study in the APP23 and WT mice (Figure 59).
3.2.3 – Voxel Based Morphometry (VBM)
The small size of mice brain and the low image contrast between GM and WM make the
exact estimation of the volume shrinkage difficult. Atrophy sometimes is not present or is
not extensive enough to involve the whole structure volume. Thus, automated voxel based
methods have been developed to identify small alterations in the volume of GM that may
be  lost  with  the  volume estimation  of  the  entire  regions.  The  VBM  (Ashburner  and
Friston,  2000) technique  was  developed  to  characterize  alterations  in  the  GM  tissue
concentration  across  human  subjects.  This  approach  was  also  described  in  the  study
transgenic mouse models (Pagani et al., 2016). 
The analysis pipeline include the following steps:
• A study  based  template  was  created  (with  the  buildtemplateparallel.sh  script)
considering  all  the  extracted  brains  obtained  within  the  automate  parcellation
procedure previously described. 
• The tissues of the template were then classified, using the Atropos command of the
ANTs  toolkit  (Avants  et  al.,  2011b),  into  six  independent  classes  that  were
subsequently merged into three classes defining the WM, the GM and the CSF
(Figure 60).
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Figure 60: Tissues probability maps of the study specific template.
• Each brain  was registered to  the study specific  template  using a  diffeomorphic
transformation that resulted in a deformation field describing how local structures
must  be  adjusted  to  match  the  template  (Figure  61).  The  voxel-wise  volume
changes  can  be  derived  from  this  deformation  field  calculating  its  Jacobian
determinant  (with  ANTSJacobian  command)  which  encodes  the  local  volume
difference between the source and target image.
• Individual tissue probability maps were then obtained from the spatially normalized
brains using Atropos command and adopting the template tissues classification as
starting prior probability images. 
• The Jacobian determinant was finally modulated using the subject GM probability
map obtained, this step allows the analysis of GM probability maps in terms of
local  anatomical  variation  instead  of  tissue  density.  More  specifically,  when  a
structure of the brain with a certain amount of GM becomes bigger/smaller during
normalization it will have larger/shorter local GM values than are truly present. The
Jacobian determinants allow the quantification of the difference between true GM
and apparent GM. 
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• The  resulting  modulated  GM probability  maps  are  smoothed  using  a  Gaussian
kernel with a sigma of three voxel width (FWHM = 0.64 mm) and employed for
voxel-wise statistical comparison.
Figure 61: Image normalization. (a) Shows how an input image and
the deformation field that must be applied to perfectly resemble a
reference image. Similarly in (b) a brain image can be warped to a
template image obtaining the Jacobian determinant. The color code
indicate that blue regions were bigger in the subject image and that
need to be contracted, on the other side region with smaller volume
need to be expanded to resemble the template and are shown in red.
Results: The test dataset composed by WT mice and APP/PS2/Tau transgenic mice of 24
months of age was again used to test the method developed. The results are shown in
Figure  62;  the  hippocampal  and  enthorinal  cortex  regions  were  significantly  bigger
(yellow enhanced regions) in WT mice when compared to transgenic mice. As expected
also the ventricle region was significantly bigger (blue enhanced regions) in transgenic
mice when compared to WT ones.
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Figure  62: VBM results of a 24 month old group of triple transgenic mice. The
upper box shows a series of the template coronal slices while in the bottom box
four  axial  views.  The  colored  superimposed  statistical  map  indicate  regions
statistically bigger (p < 0.05) in the group of WT mice, while blue regions are those
that resulted bigger in transgenic mice.
Again, VBM did not show significantly different regions between APP23 and WT mice at
all  time points  considered confirming results  obtained with the automatic  parcellation
procedure.
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3.2.3 – DTI analysis.
Within this  section the development  of the DTI analysis  protocol,  to  investigate  WM
pathology, is shown. The following pre-processing steps were adopted to prepare the DTI
images for the voxel based analysis:
• The bias field intensity was firstly corrected in all  the 2D anatomical reference
images with the N4BiasFieldCorrection tool (Tustison et al., 2010). These images,
composed of 18 slices with a thickness of 0.5 mm, were averaged to create a 2D
anatomical reference template using the buildtemplateparallel.sh script  (Avants et
al., 2011a). 
• This 2D anatomical template was co-registered with the in-house high resolution
anatomical template (created during the parcellation of hig resolution anatomical
images) in order to automatically a 2D reference brain mask. 
• A correction of the distortion due to eddy currents was applied to all DTI volumes
with the specific tool embedded in the FSL software (Andersson and Sotiropoulos,
2016). 
• The B0 image,  representing the volume acquired without  the application  of  the
diffusion gradient,  was extracted from each DTI volume, corrected for intensity
non-uniformity and normalized antsIntroduction.sh script (Klein et al., 2009) with a
non-linear greedy transformation to the 2D anatomical template. This step allowed
the creation of a brain mask for each subject by back-projecting the 2D template
brain mask. 
• The diffusion tensor was finally modeled with the dtifit tool (Jenkinson et al., 2012)
applied to the preprocessed images, obtaining the images representing the fractional
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anysotropy (FA),  the axial  diffusivity  (AD), the mean diffusivity  and the radial
diffusivity (RD). 
Once that the diffusion tensor was calculated for each DTI image, a voxelwise analysis of
whole brain white matter (WM) called “tract based spatial statistic” (TBSS) was applied
(Smith et al., 2006). It included the following processing steps:
• A group mean full tensor template was firstly created using a population-based dti
atlas  construction  algorithm  that  adopts  a  tensor  based  registration  procedure
embedded in the DTI-TK software library (Zhang et al., 2007). The template was
constructed  over  three  rigid  registration  iterations,  followed  by  three  affine
iterations and, finally, six non-linear diffeomorphic iterations with a threshold on
convergence of 0.002. The template was updated after each iteration by averaging
the  normalized  images.  The  average  template  was  resampled  to  an  in  plane
resolution of 100 × 100 μm2 and a slice thickness of 0.2 mm. The mean FA skeleton
is shown in Figure 63, which represents all the tracts “common” to all subjects, was
created  from the  mean FA image with  the  FSL tbss_skeleton  command with  a
threshold of 0.2. 
Figure 63: mean FA template in background and FA skeleton in orange.
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• The skeleton obtained was binarized and manually subdivided into 8 white matter
tract of interest (Figure 64 and 65). 
Figure  64:  Subdivision of the corpus callosum white matter tracts and their 3D
reconstruction.
Figure  65:  Subdivision  of  the  internal  white  matter  tracts   and  their  3D
reconstruction.
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• Individual  FA images were finally  normalized  to  the  mean FA template  with a
diffeomorphic transformation that was subsequently applied also to AD, RD and
MD images. Each normalized FA, AD, RD and MD image was projected onto the
mean skeleton by filling the skeleton with values from the nearest relevant tract
center. 
• Mean FA, RD, AD, MD values extracted for each subject in each tract of interest
enabling the statistical analysis (two-way ANOVA using R software).
3.2.4 – Longitudinal DTI study of the APP23 mice 
Although in a  late  stage  of  the  pathology,  the  statistical  analysis  revealed  significant
differences in most of the cortical tract selected. 
Figure  66:  Panels  representing  FA values   (expressed  as  Mean  ± s.e.m.)  of  WM tracts  presenting  a
significant interaction between age and genotype. Post-hoc test  results shown as: ****p <0.0001, ***p
<0.001,**p <0.01, *p <0.05.
FA values (Figure 66) show a significant interaction between age and genotype in the EC
(P=0.0001, F=8.0314), in the GCC (P< 1*10-6, F = 12.43), in the BCC (P=0.01, F=4.24),
106
in the SCC (P < 1*10-5, F=9.66). Although there wasn’t a significant interaction between
age and genotype, a significant effect of age and genotype was found in the IC (PAGE <
1*10-5; PGENOTYPE = 0.001) and in the FI  (PAGE = 0.003; PGENOTYPE = 0.003). In the AC just
the effect of age was significant (PAGE  < 1*10-5).
.Figure 67: MD values in the FI (expressed as Mean ± s.e.m.)
No  interaction  between  age  and  genotype  was  detected  when  the  MD  values  were
considered. However, an effect of age was seen in the GCC (PAGE = 0.004), in the BCC
(PAGE < 1*10-7) in the SCC (PAGE = 0.0002), in the IC (PAGE = 0.0001) and in the OT (PAGE
= 0.01) indicating that the two groups have a similar trend. Both the age effect (PAGE =
0.0002)  and genotpype effect (PGENOTYPE < 1*10-10) were significant in the FI indicating
that MD was impaired already at the earliest time-point and that both groups decrease
with the same trend along their lifespan (Figure 67)
The longitudinal analysis of RD values revealed a significant interaction between age and
genotype  (P= 0.006, F=4.55) only in the GCC Figure 68. A significant effect of age was
seen in AC (PAGE < 1*10-4), in the IC (PAGE = 0.0002) and in the OT (PAGE = 0.002) while a
significant difference between groups (PGENOTYPE < 1*10-4) and a significant effect of age
(PAGE < 1*10-4) but not significant interaction was seen in the FI.
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Figure  68:  RD values in the GCC (expressed as Mean  ± s.e.m.).
Post-hoc  test  results  shown  as:****p  <0.0001,  ***p  <0.001,**p
<0.01, *p <0.05.
In Figure 69 are shown tracts where the analysis found statistically significant differences
in the AD values. A significant interaction between age and genotype was found in the AC
(P = 0.006, F=4.5), in the GCC (P = 0.02, F=3.6), in the BCC (P = 0.01, F = 3.96) and in
the SCC (P = 0.0003, F=7,19). 
Figure  69: Panels  representing  AD  values  (expressed  as  Mean  ±  s.e.m.)  of  WM  tracts  presenting  a
significant interaction between age and genotype. Post-hoc test  results shown as: ****p <0.0001, ***p
<0.001,**p <0.01, *p <0.05.
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Figure 70: FA and AD values in the selected WM tract (units: 10-3 mm2/s).
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Figure 71: RD and MD values in the selected WM tract (units: 10-3 mm2/s).
3.2.5 – T2 relaxation time
T2‐weighted  imaging,  can  be  used  to  measure  signal  reductions  due  to  local  field
inhomogeneities resulting from a variety of factors. Among these, iron content has been
particularly investigated  (Haacke et al., 2005). The presence of iron potentiates reactive
oxygen species, and thus contributes to an increase of the oxidative stress implicated in
neuronal loss in many neurodegenerative disorders such as Alzheimer's disease  (Bush,
2003; Jellinger et al., 1990).
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To calculate the T2 relaxation time of the mouse brain the following steps have been
performed: 
• Images with the higher signal to noise ratio (corresponding to TE = 11ms) were
extracted from each MSME acquisition and used to create a  reference template
(with the buildtemplateparallel.sh ANTs script) that was manually masked. 
• The template  brain mask was back-projectied to  the subject  space obtaining an
automatic estimation of the brain region. 
• T2 maps were computed with a custom MATLAB script programmed to fit voxel-
wise the acquired signal within the subject brain mask as shown in Figure 72.
 
Figure 72: T2 mapping workflow. In the upper panel the images acquired at different TE (ms)
indicated on top of the slice. In the lower panel an example of the fit obtained in the voxel
indicated by the green cross and the T2 map obtained.
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• Seven roi were defined manually over the brain template (Figure 73). 
Figure 73: Region of interests defined over the brain template.
• The calculated T2 maps were normalized to the reference template by applying the
non-linear diffeomorphic transformations previously computed. 
• The T2 value was averaged in the selected ROIs and the statistical analysis (two-
way anova) was computed with R software.
3.2.6 – Longitudinal T2 evaluation
The  longitudinal  two-way  ANOVA analysis  of  the  T2  values  revealed  a  slight  but
significant interaction between age and genotype (P = 0.049; F = 2.75) only in the HPd
region. Although there was not a significant interaction, a significant effect of age and
genotype was seen in the CP (PAGE < 1*10-16; PGENOTYPE  = 0.02 ) and in the Thal (PAGE <
1*10-5; PGENOTYPE < 1*10-5) while only a significant effect of age was seen in the Ctx (PAGE
< 1*10-5), in the Fctx (PAGE < 1*10-5) and in the EntCtx (PAGE < 1*10-7).
The cortical and the hippocampal regions appeared to be significantly lower in 24 months
of age APP23 mice compared to WT littermates when a voxel-wise statististical t-test was
computed (Figure 75).
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Figure 74: T2 mean values within the ROI defined (units
ms).
Figure 75: Significance map computed with FSL randomise to compare 24 months of age
APP23 and WT mice.
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3.2.6 – Summary (2)
A multi-parametric  MRI  study  has  been  carried  out  to  characterize  the  pathological
alterations of gray and white matter in AD transgenic models. To increase the reliability
of results and the translational impact of the study, aim of this section was to develop
automated  and  operator  independent  analysis  procedures  that  resemble  the  analysis
pipelines adopted in human MRI studies. 
A multi-atlas  parcellation  procedure,  to  measure  volumes  of  brain  regions,  and  an
automated VBM analysis, to detect alterations in the GM density, were firstly developed.
The reliability of these procedures were tested on a dataset of brain structural images,
acquired and analyzed manually within the frame of a previous project. Results obtained
with the automatic procedures shows good accordance with those obtained manually. In
particular,  24 months  of  age  APP/PS2/Tau transgenic  mice compared with  WT litter-
mates showed a significant shrinkage of the hippocampus and of the enthorinal cortex and
a  significant  enlargement  of  the  ventricles.  Nevertheless,  when  applied  on  the  brain
structural images acquired longitudinally on the APP23 transgenic mice, no significant
alterations in the volumes of ROI evaluated and no alterations in GM density by means of
VBM were detected.  This is not an unexpected result because, even if the APP23 is a
transgenic model that has been widely adopted in research studies, no alterations in its
brain morphology were previously described in literature.  As shown in  Table 2, brain
atrophy is often a minor component of the transgenic mice phenotype and sometimes it is
not present when single transgenic models are studied (Borg and Chereul, 2008).
An automatic TBSS approach was developed to analyze DTI images revealing that the
APP23 mice model show detectable WM alterations only in a late stage of the pathology.
The corpus callosum of 24 months of age APP23 mice present a significant decrease of
the FA and AD (Figure 67-68) and an increased RD (Figure 70). These alterations might
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be associated both with a structural damage due to a demyelination process, resulting in
an increased freedom for water molecules to move across white matter tracts, or with the
infiltration of immune cells typical of a neuroinflammatory state (J. Zhang et al., 2012).
Supporting  our  findings,  It  has  been  demonstrated  that  a  cerebral  amyloidosis  in  the
neocortex of 27-months old APP23 mice causes a modest but significant neuron loss and
marked  gliogenesis  (Bondolfi  et  al.,  2002).  Another  study  on  aged  APP23  mice  (24
months of age)  demonstrated that  fibrillar  amyloid deposits  and associated gliosis  are
accompanied by a reduction in the apparent diffusion coefficient  (Mueggler et al., 2004).
This may suggest that the extracellular deposition of fibrillar amyloid and/or associated
glial  proliferation  cause  restrictions  to  interstitial  fluid  diffusion.  Reduced  diffusivity
within the interstitial space may alter volume transmission and therefore contribute to the
cognitive impairment.
The longitudinal  analysis  of  the  T2 relaxation  times  revealed  a  slight  but  significant
decrease in the hippocampus of aged APP23 when compared to age-matched WT. Other
region investigated showed a significant effect of age. When a voxel-wise approach was
used to compare only the 24 months of age APP23 mice with the age-matched WT a
region characterized by a decreased T2 values was found in the cortical region.  Several
factors have been described to influence the T2 relaxation time, including water content,
myelin density and by the presence of paramagnetic molecules, such as iron (Jara et al.,
2006; Paus et al., 2001). Therefore, the increased concentration of iron in the brain tissue
of patients with AD  (Connor et al., 1992) and the presence of iron in amyloid plaques
(Collingwood et al., 2008) has suggested that the measurement of the T2 relaxation time
can be considered as a possible marker of tissue characteristics easily measurable both
with preclinical and clinical settings. However, described changes of T2 time in AD have
not been consistent either in patients or in mouse models. As shown in table  Table 2,
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studies  in  transgenic  models  found significantly  greater  T2 in  young transgenic  mice
when  compared  to  WT,  while  in  older  transgenic  mice  T2  values  were  significantly
reduced. Significantly lower T2 values were found in AD patients showing a positive
correlation with cognitive scores but these results were not confirmed by other studies
that  described  inversely  that  the  increased  T2  values  found  in  the  hippocampus  are
correlated with the severity of functional and cognitive impairments in AD patients (Tang
et al., 2018).
116
3.3 – Optimization of the rsfMRI analysis workflow
As reported in  Table 2 and described by a  recent  review  (Asaad and Lee,  2018),  the
assessment of the brain functional connectivity by means of rsfMRI imaging is playing a
fundamental  role  in  the  study of  AD as  functional  alterations  are  the  primary  events
occurring the pathological cascade. The interest in this technique have recently grown
because different studies were able to observe deficits in the hippocampus and/or in the
cortex of transgenic mice, sometimes at early ages. 
This section includes the development of the processing pipeline to analyze the rodent
rsfMRI data. Preliminary experiments were carried out on rats;  this choice was made to
overcome different issues: 
• Firstly, the significant small size of mouse brain requires image acquisition at a
high spatial resolution at the expense of the signal-to-noise ratio. This problem may
be compensated by the use of last generation of radiofrequency cryogenic coils that
can boost the signal-to-noise ratio minimizing the thermal noise influence. The only
mouse coil configuration available at the beginning of this study was characterized
by a lower signal-to-noise ratio when compared to the available quadrature receiver
coil for the rat brain. We were able to install a cryogenic coil system for the mouse
brain only at the beginning of 2018. 
• Secondly, since the  conditions affecting the cerebral blood flow could lead to an
incorrect interpretation of the observed changes in brain activity a great care in the
use of anesthesia is needed and the bigger size of rats makes the anesthesia protocol
easier to perform in rats. Although it is necessary to minimize the animal movement
and to enable the imaging acquisition, anesthesia can alter the physiology and the
brain activity of animals leading to results that are not representative of the awake
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state (Grandjean et al., 2014; Liang et al., 2012). To avoid the suppression of signal
arising  from  the  brain  activation,  animals  must  be  kept  sedated  without  the
induction of a deep anesthesia state. Isofluorane at 1,5-2% is able to suppress brain
activity  (Liang et  al.,  2015) while  a  dose-dependent  decrease  of  the  functional
connectivity was found with the use of medetomidine (Nasrallah et al., 2014). The
combined use of low doses of medetomidine and isoflurane was suggested as it
retained strong correlations both within cortical and subcortical structures, without
the potential  seizure-inducing effects  of  medetomidine  (Grandjean et  al.,  2014).
Some  research  groups  have  recently  shown  that  a  mechanical  ventilation  in
combination  with  the  administered  anesthetic  and  an  injection  of  pancuronium
bromide, a muscle relaxant that allow the minimization of animal movements, are
needed to obtain reliable results in mice studies (Bertero et al., 2018; Zerbi et al.,
2015). 
• In the end, since a great care in the optimization of the analysis protocol must be
adopted we decided, in collaboration with Luigi Cervo research group, to induce
functional  connectivity  alterations  by  means  of  a  pharmacological  challenge.
Different published rsfMRI studies in rats  were able  to  detect strong functional
alterations  after  the injection of a  pharmacological  challenges such as ketamine
(Gass et al., 2014; Grimm et al., 2015) or nicotine (Gozzi et al., 2006; Z. Li et al.,
2008;  Bruijnzeel  et  al.,  2014).  This  experiment  enabled the  optimization of  the
analysis  procedure  since  the  expected  functional  alterations  must  have  been
detected after the injection of a pharmacological challenge.
The aim of the presented work is to develop a reliable analysis pipeline to be translated to
future rsfMRI studies in AD transgenic mouse models.
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3.3.1 – rsfMRI analysis pre-processing
The analysis pipeline adopted was recently introduced within the frame of the Human
Connectome Project and its efficacy has been recently demonstrated in the analysis of
mouse rsfMRI data  (Zerbi et al.,  2015).  It is characterized by the removal of artifact
components  by  automatic  classification  carried  out  by  the  FMRIB’s  ICA-based
Xnoiseifier  (FIX)  (Salimi-Khorshidi  et  al.,  2014)  software  which  does  not  need  the
recording of external physiology (e.g. respiration or cardiac cycle) or the segmentation of
CSF and WM. 
To make possible the identification of different functional networks, different steps were
implemented to pre-process the rsfMRI raw data:
• A slice  timing  correction  was  initially  applied  to  the  fMRI  timeseries  (SPM8)
followed by a realignment with motion parameter estimation and a correction for B0
inhomogeneities (FieldMap toolbox SPM8). 
Figure 76: The effect of the B0 inhomogeneity correction. Within the upper box the acquired image
is shown. The effect of the unwarping correction is higlighted by yellow arrows in the bottom box.
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Few coronal slices of the native image are shown in the upper frame of Figure 76
while  in  the lower frame it  can be seen how the FieldMap toolbox is  able  to
compensate the main deformations caused by the B0 inhomogeneities.
• Each anatomical reference scan was spatially normalized, through linear affine and
nonlinear diffeomorphic transformation metric mapping with the ANTs software
(Avants et al., 2011a), to a rat brain template  with co-registered anatomical atlas
positioned in the Paxinos stereotactic coordinate system (Schwarz et al., 2006). In
order to improve the spatial normalization quality, an in-house brain template was
created by averaging the obtained normalized anatomical images. Each anatomical
reference  was  then  anew  spatially  normalized  with  a  greedy  non-linear
transformation to the study specific template. The transformations obtained were
used  to  back-project  to  each  subject  space  the  template  brain  mask  label,
performing an automatic brain extraction also of the fMRI data. 
• 50  independent  components  were  estimated  for  each  brain  extracted  fMRI
timeseries  using  FSL  MELODIC  (Multivariate  Exploratory  Linear  Optimized
Decomposition  of  Independent  Components)  (Beckmann  and  Smith,  2004;
Jenkinson et al., 2012). 
• On a random subset of 20 timeseries, a hand-classification of the ICA components
into signal (Figure 77) and noise derived from respiratory motion (Figure 78) and
cardiac motion (Figure 79) was made on the basis of different factors previously
described (Pan et al., 2015; Zerbi et al., 2015).  Firstly, the shape of the thresholded
spatial  maps  that  must  resemble  the  shape  of  previously  described  activation
components  while  in  case  of  respiratory  and  cardiac  noise  can  be  identified
respectively on the edge of the brain and in correspondence of the main vessels on
the  bottom  of  the  brain.  Secondly  the  temporal  power  spectrum  of  a  signal
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component  have  a  low  frequency  fluctuation  (Figure  77)  while  the  noise
components present spikes at higher frequency (Figure 78 and 79). The components
that  were  not  easily  identified  as  one  of  the  three  described  categories  were
assigned as unknown component. 
Figure 77: Example of a signal components which exhibit a low frequency fluctuations.
Figure 78: Respiratory effects can be localized near the midline, the ventricles, and the surface of
the brain.
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Figure  79: Cardiac artifact are associated with regions along the surface and at the base of the
brain.
• These classified ICA components were used as a training set for FSL-FIX (Griffanti
et al., 2014; Salimi-Khorshidi et al., 2014). After training, a “soft” artifact removal
of motion parameters and noise components of all datasets was applied using FSL-
FIX. 
• Each denoised fMRI timeseries was finally spatially normalized to the in-house
template by applying the transformations previously obtained. Normalized images
have a final resolution of 2 × 2 × 2 mm3.
Two methodologies are widely used for evaluating the functional connectivity rsfMRI
data:  The  spatial  independent  component  analysis  (ICA),  which  is  a  mathematical
technique that identifies functional networks maximizing their  statistical  independence
(Beckmann  et  al.,  2005);  And  the  seed  based  analysis  (SBA)  which  allow  the
identification of functional networks through the temporal correlation of a specified seed
voxel with the rest of the brain voxels (Biswal et al., 1995; Joel et al., 2011). 
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To establish  the consistency of the observed variations,  both analysis techniques were
developed since ICA derived network maps have shown similar connectivity  maps to
those obtained with the SBA.
3.3.2 – Independent component analysis (ICA)
The assessment  of  the  resting-state  functional  connectivity  was  carried  out  following
these steps:
• The temporal concatenation,  using the FSL MELODIC software,  of all  the pre-
processed  and  normalized  fMRI  timeseries  allowed  the  extraction  of  50  ICA
components (ICs). A subset of 18 ICs (Figure 80) was selected through a visual
comparison with previously reported networks in rats and mice  (Jonckers et al.,
2011; Liang et al., 2011; Bukhari et al., 2017; Grandjean et al., 2017). 
Figure 80: Selected  ICs components representing the principal resting state networks identified. 1-
Motor Cortex;  2 – Insular Cortex;  3 – Cingulate Cortex;  4 and 9 – Somaosesory Cortex;  5 –
Hippocampus dorsal;  6 – Thalamus + Hippocampus ventral;  7 – Ventral  Striatum; 8 and 14 –
Orbitofrontal Cortex; 10 - Lateral Striatum; 11 – Dorsal Striatum; 12 – Retrosplenial Cortex; 13 –
Barel field Cortex; 15 – Visual Cortex; 18 – Auditory Cortex.
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This subset of 18 ICs represent the functional template of networks to be used in
the following steps.
• A dual regression approach was applied to regress out the time courses and the
spatial  distribution  of  the  initially  identified  50  ICs  for  each  fMRI  acquisition
(Beckmann et al., 2009; Cole et al., 2010; Filippini et al., 2009; Nickerson et al.,
2017). As shown in Figure 81, in the first step of dual regression, the full set of 50
ICs (including identified networks and artifact components) were used in a multiple
spatial regression against each dataset resulting in a set of matrices (time points x
components)  representing  the  average  time  course  of  voxels  in  each functional
network for each subject. The normalized time courses were subsequently used in a
second multiple regression step to identify unique spatial maps for each subject,
representing the brain regions correlating with each time course. 
Figure 81: Flowchart showing the dual regression workflow. The regression of the template spatial
maps  into  each  subject  space  allow the  estimation  of  subject  specific  spatial  maps  and  relative
timecourses.  The extracted subject specific timecourses are used to make a comparison  between
components.  While the subject  specific  spatial  maps are used to evaluate differences  within the
component identified.
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• Alterations  of  the  connectivity  between the  identified  RSNs  were  investigated
using  FSL-Nets  (Jenkinson  et  al.,  2012).  Each  matrix  of  time  courses  was
processed firstly by removing the artifact components and cleaning up the residual
time-courses  representing  the  identified  RSNs.  A  network  matrix  was  then
computed,  using  normalized  covariance  and  transformed to  Fisher-z  scores,  for
each  subject.  In  order  to  investigate  the  effect  of  nicotine  on  the  correlation
between RSNs, the difference between the network matrix post-injection and the
network matrix pre-injection was computed for each subject. 
• Alterations  of  the  connectivity  within the  RSNs  identified  were  assessed  by
evaluating the changes of the spatial correlation obtained in the second step of dual
regression. For each subject, a subtraction of the spatial maps of the components
obtained with the post-injection dataset  to  those obtained with the pre-injection
dataset was computed.  The average delta correlation was than computed over a
region  obtained  by  applying  a  threshold  (Z  >  4)  and  a  binarization  to  the
corresponding component of the template. A spatial-correlation matrix representing
the correlation intensity alteration within each component was in the end created
for each subject.
• A one-way anova was finally applied (Matlab) to the networks-matrices and to the
spatial-correlation  matrices.  The  evaluation  of  the  nicotine  effect  was  assessed
respectively between and within each identified network and whether this effect is
dependent on the dose injected.  A post-hoc test  was applied just  to connections
found to be significantly different between groups.
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3.3.3 – Within component ICA analysis 
Our analysis shows a significantly increased correlation after the injection of a nicotine
bolus at a dose of 0.1 g/kg within some of the selected components. This increase was not
seen after the injection of a saline solution or after the injection of a lower dose of 0.05
g/kg or when a bolus of mecamylamine was administered after the injection of nicotine at
0.1 g/kg. In  Figure 82 to  96 the variation of the correlation, expressed as the difference
between post and pre-injection correlation value (Δz), in the four experimental groups is
shown. Only components that showed a statistical significant difference between groups
are shown. The results of the statistical analysis is reported in each figure where outliers
are shown as red crosses and post-hoc tests results are indicated with ***p <0.001,**p
<0.01, *p <0.05.
 
Figure 82: Nicotine effect on the ica component 1. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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Figure 83: Nicotine effect on the ica component 2. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
Figure 84: Nicotine effect on the ica component 3. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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Figure  85Nicotine effect on the ica component 4 . Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
Figure 86: Nicotine effect on the ica component 5. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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Figure 87: Nicotine effect on the ica component 6. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
Figure 88:  Nicotine effect on the ica component 7. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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Figure 89:  Nicotine effect on the ica component 8. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
Figure 90:  Nicotine effect on the ica component 9. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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Figure 91: Nicotine effect on the ica component 10. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
Figure 92: Nicotine effect on the ica component 11. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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Figure 93: Nicotine effect on the ica component 12. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
Figure 94: Nicotine effect on the ica component 13. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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Figure 95: Nicotine effect on the ica component 15. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
Figure 96: Nicotine effect on the ica component 18. Left panel shows its location and right
chart show the difference of the correlation (ΔZ) due to the pharmacological challenge.  F
and P values are highlighted on top of the chart  (***p <0.001,**p <0.01, *p <0.05) red
crosses indicate the outliers excluded.
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3.3.4 – Between component ICA analysis
Using the nets_hierarchy.m script embedded into FSLNets, it  is possible to cluster the
selected components to form larger resting-state networks basing on their timeseries. In
Figure 97 the correlation between the time series of each component with the others 17 is
denoted within each column. It can be seen that three networks were identified. 
Figure 97: Hieratical network plot of the 18 selected components. Dark red indicates a highly
positive correlation and dark blue represents highly negative correlation.  Self-correlation is
represented with gray values. On top of the matrix the tree plot represent the clustering of the
networks that are also highlighted in the matrix with the same colors.
The difference of all the correlation values, shown in Figure 97, was computed between
post  and  pre-injection  (Δz)  for  each  subject.  The  one-way  ANOVA  analysis  was
subsequently carried out to compare the four experimental groups. Results are shown in
Figure 98 to  105. An increased synchronization between components belonging to the
same network was detected.  In particular, a significant increased correlation between two
of the components belonging to the basal ganglia network (ICA 10 and 11) corresponding
to  the  ventral  and lateral  striatum was seen  after  the  injection  of  the  higher  dose  of
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nicotine (Figure 98).  Similarly, a significant increased correlation between three of the
components belonging to the DMN (composed by ICA 3, 12,14) was seen (Figure 99 to
101). Moreover, a significant decrease in the correlation between components belonging
to different networks was seen after the injection of 0.1 g/kg of nicotine (Figure 102 to
105).
Figure 98: Effect of the nicotine administration on the correlation between component 10 and 11.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc
tests results are indicated with ***p <0.001,**p <0.01, *p <0.05.
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Figure 99: Effect of the nicotine administration on the correlation between component 12 and 3.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc
tests results are indicated with ***p <0.001,**p <0.01, *p <0.05.
Figure 100: Effect of the nicotine administration on the correlation between component 14 and 12.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ  represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc tests
results are indicated with ***p <0.001,**p <0.01, *p <0.05.
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Figure 101: Effect of the nicotine administration on the correlation between component 14 and 3.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc
tests results are indicated with ***p <0.001,**p <0.01, *p <0.05.
 
Figure 102: Effect of the nicotine administration on the correlation between component 10 and 3.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc
tests results are indicated with ***p <0.001,**p <0.01, *p <0.05.
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Figure 103: Effect of the nicotine administration on the correlation between component 11 and 3.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc
tests results are indicated with ***p <0.001,**p <0.01, *p <0.05.
Figure 104: Effect of the nicotine administration on the correlation between component 12 and 10.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc
tests results are indicated with ***p <0.001,**p <0.01, *p <0.05.
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Figure 105: Effect of the nicotine administration on the correlation between component 12 and 11.
Left panel represent the three-dimensional reconstructions of the two ICA considered. Results of
the  statistical  analysis  are  represented  in  the  right  panel.  ΔZ represents  the  difference  in  the
correlation between the two components. Outliers are represented by red crosses and post-hoc
tests results are indicated with ***p <0.001,**p <0.01, *p <0.05.
3.3.5 – Seed based analysis (SBA)
To assess the strength of the results obtained with the dual regression approach a SBA
was carried out. This approach allow the assessment of the correlation between the time-
course extracted in defined seed regions. Thus:
• A set of small seed regions of 3 × 3 × 3 voxels (corresponding to a 0,6 × 0,6 × 0,6
mm3 volume) were selected (Figure 106) in the ventral and dorsal striatum, in the
nucleus accumbens and in the region corresponding to the hippocampal-prefrontal
network including the orbitofrontal, prefrontal, cingulate and retrosplenial cortices
and the hippocampus  (Adam J. Schwarz et al., 2013; A. J. Schwarz et al., 2013).
Mean  time-courses  from  each  seed  were  extracted  and  inter-seed  connectivity
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matrices were obtained with FSL-Nets calculating the normalized covariance and
transformed to Fisher-z scores. 
Figure  106:  Seed positioning (Left)  and  matrix  showing the mean correlation values  (Z)
between the timecourses extracted in the baseline acquisition. Abbreviations: Motor cortex
(Mot ctx),  Orbito Frontal  Cortex (OFC), Nucleus accumbens (Nac) and Insula (Ins).  The
color-coded scale indicate positive correlations (Z > 0) with a red tonality, while negative
correlation (Z < 0) are shown in a blue tonality indicating an anti-correlation between the two
seed considered. 
• The  inter-seed  connectivity  matrices  representing  the  pre-injection  dataset  were
subtracted to the post-injection ones, obtaining a matrix of delta values for each
subject. 
• To evaluate  the  effect  of  the  pharmacological  challenge,  a  one-way anova  was
applied to compare the delta-connectivity matrices of the four groups (Figure 107).
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Figure 107: Seed analysis workflow. The time-course of each seed is extracted from each acquisition.
The  correlation  between  all  seed  is  computed  and  the  difference  between  pre  and  post  injection
correlation used to perform the statistical comparison. 
Matrices of significance within this section are presented as (1 – P) rather than P values.
Results of the SBA analysis are shown in Figure 108, it shows two matrices representing
the F and P values obtained with the one way ANOVA. It can be seen that connections
positioned into the cingulate and retrosplenial cortex (seeds 5 to 15), striatum (seeds 21 to
25) and hippocampal regions (seeds 16 to 20) present significantly different correlations
between groups. A post-hoc tukey test was applied to connections significantly different
between groups (P < 0.95) that are highlighted in the upper part of the matrix shown in
Figure 108b.
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Figure 108: Matrices of the F-values (a) and P-values (b) obtained with the one way ANOVA analysis. Red
squares,  on the left  panel,  highlight the group of  seeds positioned into the cortical,  hippocampal and
striatal regions. The upper part of these matrices contains only connections significantly different between
groups [(1-P) > 0.95].
To ease the comprehension of results, the matrices representing the outcome of post-hoc
tests  (Figure  109 to  114)  were  separated  into  two  different  matrices  presenting
connections  that  increase  or  decrease  its  strength  after  the  pharmacological  challenge
injection. 
No significant differences are present when the group that received the saline solution
was compared to the group that received 0.05g/kg of nicotine (Figure 109). Similarly, no
difference were found when the group that received the saline solution was compared
with the group injected with a dose of 0.1g/kg of nicotine followed by the mecamylamine
dose (Figure 110). No differences was seen also when the group that received 0.05 g/kg of
nicotine  is  compared  to  the  group that  received  0.1g/kg of  nicotine  followed  by the
mecamylamine dose. This suggests that the lower dose of nicotine does not influence the
brain  connectivity  in  rats.  A statistically  significant  difference  can  be  seen  when rats
received the 0.1 g/kg dose of nicotine (Figure 111, 113, 114). Similarly to what has been
shown with the ICA analysis, seeds belonging to the same functional network show an
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increased correlation after the injection of the higher dose. Thus seeds positioned within
the cortical  regions show increased connectivity and similarly seeds positioned within
striatal  regions.  A decreased  correlation  was  also  seen  between  seeds  belonging  to
different networks, such as seeds placed in the cingulate and retrosplenial cortex region
with those placed in the striatal region. 
Figure 109: One way anova post-hoc analysis comparing the effect of the saline injection with the nicotine
at a dose of 0.05 g/kg. (a) and (b) matrices contain connections that show significantly decreased and
increased correlations. (c) and (d) show the three-dimensional representation of the above matrices.  
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Figure  110: One way anova post-hoc analysis comparing the effect of the saline injection with the
nicotine at a dose of 0.1 g/kg followed by the mecamylamine injection. (a) and (b) matrices contain
connections that show significantly decreased and increased correlations. (c) and (d) show the three-
dimensional representation of the above matrices.  
Figure  111: One way anova post-hoc analysis comparing the effect of the saline injection with the
nicotine at a dose of 0.1 g/kg. (a) is the matrix and (c) the three-dimensional representation of the
connections  showing significantly  decreased  correlations  between cortical  and  hippocampal  seeds.
Increased correlations within cortical and within striatal regions are shown in (c) and (d).
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Figure 112: One way anova post-hoc analysis comparing the effect of the nicotine at a dose of 0.05
g/kg with the nicotine at a dose of 0.1 g/kg followed by the mecamylamine injection. (a) and (b)
matrices contain connections that show significantly decreased and increased correlations. (c) and (d)
show the three-dimensional representation of the above matrices.  
Figure 113: One way anova post-hoc analysis comparing the effect of the nicotine at a dose of 0.05
g/kg with the nicotine at a dose of 0.1 g/kg. (a) and (b) matrices contain connections that  show
significantly  decreased  and  increased  correlations.  (c)  and  (d)  show  the  three-dimensional
representation of the above matrices.  
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Figure  114: One way anova post-hoc analysis comparing the effect of the nicotine at a dose of 0.1 g/kg
with the nicotine at a dose of 0.1 g/kg followed by the mecamylamine injection. (a) and (b) matrices
contain connections that show significantly decreased and increased correlations. (c) and (d) show the
three-dimensional representation of the above matrices.  
3.3.7 – Summary (3)
The translation of an optimized rsfMRI analysis pipeline, that was recently introduced
within the frame of the Human Connectome Project, was shown within this section. This
pipeline include a preprocessing step, carried out with the FSL-FIX software aimed to
clean the noise components induced by respiration and cardiac movement, and a post
processing  step,  to  assess  the  functional  connectivity.  The  two  widely  adopted  post-
processing procedures (the dual-regression and the seed analysis) have been described
and evidences that these are able to provide similar outcomes given. The reliability of the
analysis pipeline adopted was assessed through a preliminary experiment that was carried
out  using  rats  instead  of  mice.  This  choice  has  been  taken  to  ease  the  experimental
conditions. The use of rats present different experimental advantages such as the size of
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the brain and the better signal to noise ratio of the available surface coil. Moreover, to
alter the functional connectivity of healthy rats a pharmacological challenge of nicotine
has been injected and the effect of the doses investigated. 
Results  shown  highlight that  the  application  of  the  presented  analysis  pipeline  have
enabled  the  detection  of  an  altered  functional  connectivity  due  to  the  acute  nicotine
administration with a dose of 0.1 mg/kg. We could infer that the observed variations are
caused by the nicotine injection since no differences have been observed with the saline
challenge or when a  mecamylamine,  a non-selective and non-competitive antagonist of
the nicotinic acetylcholine receptors (nAChRs), was administered after nicotine. Since the
described  functional  alterations  were  obtained  with  two  different  post-processiong
procedures, the ICA and the SBA, we can confirm that the experimental set-up adopted
was reliable. 
The goodness  of  results  obtained is  supported  also  by  the  fact  that  the  maps  shown
(Figure 115) present  a  robust  anticorrelations between midline DMN-like regions  and
lateral cortical areas, which is a fundamental feature of the DMN previously described
also in mice and humans (Adam J. Schwarz et al., 2013; Gozzi and Schwarz, 2016). 
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Figure  115:  Cropped  version  of  Figure  30 showing  the
measured anti-correlation between the cortical  components
(ICA3,  12)   and  the  lateral  network  components  (ICA
1,2,9,13,16)
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Chapter 4 – Discussion and Conclusions
The  objective  of  this  thesis  was  to  develop  a  multi-parametric  framework  of  MRI
techniques and operator  independent  analysis  workflows able to describe most of  the
pathological alterations of the AD.
4.1 – Technical advancements
The major finding of the work was that the 2DG-CEST technique enabled, for the
first  time  in  a  transgenic  mouse  model  of  AD,  the  detection  of  the  impaired  brain
metabolism. Compared to the only previously published study on an AD mouse model
(Wells et al., 2015), we focused on the region of the Z-spectrum affected by the presence
of  hydroxyl  protons  belonging  to  the  2DG.  Since  it  is  not  metabolized,  it  remains
internalized in the cells longer than glucose and it can be used to enhance the technique
sensitivity. Our result indicates that the CEST technique is able to highlight a reduction of
2DG brain uptake at 20-month-old of age in the APP23 mice compared to WT mice.
Differences in the brain metabolic activity can be detected within a few minutes after the
injection of 2DG, and persisted for over an hour (Figure 47 and 52) in the cortex area.
The blood 2DG contribution could be considered negligible and the increase in CEST
asymmetry is mainly due to the extra-vascular concentration of 2DG and its metabolic
product (2DG6P), which accumulates in cells.  To our knowledge, only one study has
been published in the APP23 mice with [18F]FDG-PET, showing no changes in glucose
metabolism at 13 months of age (Heneka et al., 2006). Moreover, even if hypometabolism
is one of the earliest events in a subclinical stage of the pathology and progresses with age
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(Mosconi et  al.,  2010, 2009), studies in AD mice models with [18F]FDG-PET show a
complex framework (see  Table 2). The variability between these studies may be linked
both to the intrinsic heterogeneity of transgenic mouse models and to issues related to
differences in microPET acquisition parameters. Environmental factors (e.g. temperature,
fasting time, stress level) could also affect mouse metabolism adding variability between
different studies (Deleye et al., 2016; Goertzen et al., 2012; Kuntner et al., 2009).
The described analysis pipeline have further advantages such as the automatic and robust
data analysis. The correction of B0 and B1 inhomogeneities (done here using a WASABI
(Schuenke  et  al.,  2016) sequence)  is  essential  in  order  to  translate  the  technique  to
humans, where static and excitation fields may present wide variability over the whole
brain. The co-registration of GCE maps on a brain template enable to avoid mistakes due
to manual tracing and permits a voxel-wise analysis.  
Besides the steady-state acquisition, a dynamic acquisition covering the first 15 minutes
after  2DG  infusion  was  also  acquired.  We calculated  the  AUCDyn and  no  significant
differences were detected in the dynamic acquisition during the infusion but there seemed
to be a clear trend toward a more pronounced delivery of glucose in wild-type mice than
transgenic mice at 20 months of age (Error: Reference source not found and  50). The
interpretation of dynamic data is less straightforward than data obtained at longer times.
To reduce the sampling time and to observe dynamic changes in the blood flow, it is not
possible to acquire the whole Z-spectrum and integrate it.  The acquisition of a single
saturation frequency repeated every 9 seconds is hindered by the impossibility of B0 and
B1 corrections, making this kind of measurement much more sensitive to fluctuations,
leading  to  less  robust  results.  Analyzing  the  Z-spectrum  with  a  multi-pool  fitting
procedure permits the calculation of the asymmetry curve over a region of interest in the
frequency  offsets,  reducing  the  noise  contribution  in  the  evaluation  of  the  effects
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observed. The signal change in the proximity of the injection may be the result of a mixed
concentration of 2DG between extracellular glucose and the plasma fraction still present.
Similarly the ventricles show an increased signal detected immediately after the injection
through  the  dynamic  acquisition.  This  effect  disappears  by  the  time  of  the  first  Z-
spectrum acquisition (14 min after injection) which might be explained by a washout of
2DG from the ventricles where no accumulation is expected. 
Few  limitations  in  the  reported  study  are  present.  Firstly,  anesthesia  is  needed  in
preclinical studies, but it can inhibit glucose uptake in the brain (Lundgaard et al., 2015;
Toyama  et  al.,  2004);  the  use  of  a  mechanical  ventilator  could  help  to  control
physiological parameters and reduce the variability. Secondly, adopting slightly different
saturation procedures, like the spin-lock, it would be possible to use higher saturation
power and shorter irradiation pulses enhancing the sensitivity of the technique and thus
the use of lower 2DG doses (Jin and Kim, 2014; Jin et al., 2016). A similar approach has
already been tested in oncology in humans (Paech et al., 2017; Schuenke et al., 2017a).
Lastly, the detection of fast-exchanging OH-proton groups could become difficult at field
strength  lower  than  7T  making  difficult  the  translation  of  this  technique  to  clinical
scanners which are commonly 1,5 or 3T (van Zijl et al., 2018). 
Alongside with the longitudinal 2D-CEST study a multi-parametric MRI study has
been carried out on the same cohort of mice to characterize their brain morphology, the
brain structural connectivity and whether alterations in the T2 relaxation time are present.
No differences in the brain morphology of APP23 mice were detected in our study or
have been previously described in literature. Even if the APP23 is a transgenic model that
has been widely adopted in research studies, this is not an unexpected result. As shown in
Table 2, brain atrophy is often a minor component of the transgenic mice phenotype and
sometimes it is not present when single transgenic models are studied (Borg and Chereul,
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2008). Indeed, there are different methodological aspects that must be taken into account
with such studies. The small size of mice brain and the low image contrast between GM
and WM make the exact estimation of the volume shrinkage difficult. To overcome these
limitation, the imaging of post-mortem brains have been adopted to increase the quality of
results since it can boost the signal-to-noise ratio, as there is no motion, longer scan times
can be acquired and the use of contrast agents in high concentrations is allowed (Holmes
et al., 2017). However, the use of live animals do not suffer of distortions and dehydration
from fixation, which may afflict the integrity of the tissues. More importantly, in-vivo
imaging permits longitudinal studies and the reduction of animal needed in research. To
increase the quality of in-vivo images, it become fundamental the use of cryogenic coils
enabling the increase of the signal and contrast within acquisition times coherent with the
length of the anesthesia (Baltes et al., 2009). Beside, the adoption of automated analysis
procedures originally developed in human research can be a valuable tool since voxel
based approaches able to determine atrophy more accurately by using stereotactic maps of
the  brain  regions.  Such  analysis  procedures  have  also  the  advantage  to  be  operator
independent  and  to  ease  the  burden  of  time-consuming  manual  delineation  of  ROIs
increasing the reproduciblity of results.
In addition to mouse studies, a preliminary rsfMRI experiment was performed in
rats.  The advantageous experimental  condition enabled by the use of rats  enabled the
development  of  a  reliable  analysis  pipeline  that  was  translated  directly  from  human
studies. Results described highlight that the application of the presented analysis pipeline
have enabled the detection of an altered functional connectivity due to the acute nicotine
administration with a dose of 0.1 mg/kg. Previously published studies were not able to
detect significant variations below a dose of 0.3 mg/kg (Bruijnzeel et al., 2014; Gozzi et
al.,  2006).  For  the first  time in  rats,  a  decreased functional  connectivity  between the
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prefrontal cortex and the striatum after the injection of nicotine was shown. The same
networks have been found to be involved in human studies of addiction  (Janes et al.,
2012). 
4.2 – Relevance in AD research
The description of the AD pathology and the understanding of its causes is complicated
by the concomitant  presence of  different  events;  such as  the accumulation  of  the Aβ
peptide as extracellular plaques and of the intracellullar NFT but also the presence of
chronic neuroinflammation and astrogliosis. The failure of several trials (Mangialasche et
al., 2010) have shown how it is difficult to treat symptoms after the disease onset and that
cognitive  skills  are  not  easily  recovered  at  later  stages.  Newly  discovered  treatments
should be administered several years before the onset of the pathology to be effective,
since  Aβ deposition  starts  before  the  cortical  tau  pathology and the  onset  of  clinical
symptoms. Within this frame, the use of transgenic models could ease the development of
new imaging  biomarkers  enabling  the  anticipation  of  the  diagnosis  and  making  new
treatments more effective (Marizzoni et al., 2013).
Thus,  in spite  of  the  limitations  characterizing  the  2DG-CEST technique,  it  offers  a
promising  alternative  [18F]FDG-PET  for  the  study  of  neurodegenerative  diseases
avoiding the need of radioactive tracers. 
Moreover,  developing  automatic  analysis  pipelines  to  study  longitudinally  the  brain
morphological  alterations  in  transgenic  mice  it  is  possible  to  identify  homologous
imaging biomarkers in humans and mice, key elements to predict reliable results in drug
testing.
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In the end, the study of the brain functional connectivity by means of rsfMRI imaging is
playing a fundamental role in the study of AD as functional alterations are the primary
events occurring the pathological cascade. Resting state fMRI in AD patients has revealed
decreased  functional  connectivity  between  numerous  cortical  brain  regions  and  the
hippocampus  (Greicius  et  al.,  2004;  Sheline et  al.,  2010).  Thus,  the  interest  in  fMRI
studies of AD transgenic models has recently increased because such they were able to
observe deficits in the hippocampus and/or in the cortex of transgenic mice, sometimes at
early ages (Asaad and Lee, 2018).. 
4.3 – Future perspectives
I hope that the presented work will be a useful starting point for future investigations.
Different MRI acquisitions and analysis pipelines have been proposed. With these, the AD
transgenic  mouse  models  can  be  characterized  obtaining  data  about  the  functional,
metabolic and structural brain modifications. 
The  improvement  of  the  2DG-CEST  sensitivity  will  be  fundamental  to  enable  the
reduction of injected doses and thus a better physiology. It can become a powerful tool in
drug discovery research and thus we must explore whether this method is able to detect
changes in the brain glucose metabolism induced by pharmacological treatments.
A mild phenotype characterized by metabolic and structural deficit in a late stage of the
pathology was described in the APP23 transgenic mouse. One of the issues characterizing
these  “first  generation”  models  is  that  they  present  mutations  that  cause  an  over-
production of total Aβ from APP that may lead to potential artifacts (Mucke et al., 2000).
Future experiments will be carried out adopting the “second generation” APPNL-G-F and
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APPNL-F  transgenic mice that were engineered to overproduce pathogenic Aβ without
over-expressing APP (Saito et al., 2014; Sasaguri et al., 2017). 
The advanced pipeline developed to investigate structural and functional alterations of the
transgenic  mouse  brain  will  be  soon  adopted  into  a  study  involving  different  Italian
research centers. As currently done in clinical studies, the standardization of acquisition
parameters and of the analysis procedures between different research groups enables a
further reduction of animals involved in research and the improvement of reproducible
results. 
Even if the described rsfMRI experiment was carried out in rats it was a necessary step to
develop a reliable analysis procedure that will be translated to future studies in transgenic
mouse models of AD. 
The  recent  acquisition  of  a  cryogenic  coil  for  the  mouse  head  and  of  a  mechanical
ventilation system will put us in condition to improve all the methods shown. A better
signal-to-noise  will  enable  to  improve  the  resolution  of  the  acquired  images,  with
particular advantages for the 2DG-CEST and for the rsfMRI ones.
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